新版　がん・生殖医療

出版社： 医歯薬出版
著者：
発行日： 2020-04-25
分野： 臨床医学：外科  >  産婦人科学
ISBN： 9784263731949
電子書籍版： 2020-04-25 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

13,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

13,200 円(税込)

購入する

商品紹介

がん治療と生殖医療の進歩により，妊孕性温存ができる小児・AYA（思春期・若年）世代のがん患者が増えている．
本書は妊孕性温存の基礎・臨床の最新知見から，がん・生殖医療連携の構築，さらにはヘルスケアプロバイダーによる支援までを幅広く紹介．
初版より，内容・執筆者を全面的に刷新し，最新情報を網羅した増補全面改訂版（20項目追加，120頁増ページ）．
がん治療医，生殖医療専門医をはじめ，看護師，臨床心理士などすべての専門医療スタッフの必携書！

目次

  • 第1章　妊孕性温存の基礎
    　01　卵子の発生と受精─その特殊能力と課題
    　02　精子の発育
    　03　卵巣の予備能
    　04　ARTのリスク
    　05　化学療法による卵巣毒性
    　06　化学療法による精巣毒性
    　07　放射線療法による性腺毒性，子宮毒性

    第2章　妊孕性温存を考慮すべき疾患
    　08　乳がん患者の現況─治療の進歩
    　09　がん患者の現況（血液疾患・白血病，リンパ腫）
    　10　がん患者の現況（男性：精巣腫瘍など）
    　11　小児がん患者の現況
    　12　免疫疾患と若年患者
    　13　がん患者の現況（骨・軟部腫瘍）
    　14　がん患者の現況（消化器腫瘍）
    　15　がん患者の現況（脳腫瘍）
    　16　がん患者の現況（遺伝性腫瘍）
    　17　がん患者の現況（卵巣がん）
    　18　がん患者の現況（子宮頸がん）
    　19　がん患者の現況（子宮体がん）
    　20　子宮内膜症と妊孕性

    第3章　妊孕性温存療法の実際
    　21　卵子凍結
    　22　胚凍結
    　23　卵巣組織凍結
    　24　卵巣組織移植
    　25　卵巣保護（GnRHアゴニスト）
    　26　全身放射線照射における卵巣遮蔽
    　27　子宮頸がんに対する妊孕性温存療法─トラケレクトミーを中心に
    　28　卵巣移動術─子宮頸がんにおける適応を中心に
    　29　子宮体がんに対する妊孕性温存療法
    　30　卵巣がんに対する妊孕性温存療法
    　31　精子凍結
    　32　精巣組織凍結
    　33　TESE

    第4章　がん・生殖医療を支える医療
    　34　周産期の立場から考えるがん・生殖医療
    　35　小児・思春期がん患者の晩期合併症と長期フォローアップ
    　36　生殖医療における精神的サポート
    　37　がん・生殖医療と看護（がん）
    　38　がん・生殖医療と看護（生殖）
    　39　がん患者と心理士との関わり
    　40　がん・生殖医療と心理社会的サポート
    　41　がん・生殖医療と薬剤師の関わり情と課題源
    　42　がん・生殖医療と里親制度・特別養子縁組制度
    　43　がん・生殖医療における女性ヘルスケア
    　44　がん・生殖医療の倫理
    　45　わが国におけるがん・生殖医療ネットワークの現状
    　46　がん・生殖医療と経済的負担

    第5章　妊孕性温存療法の試み─ガイドラインなど
    　47　日本がん・生殖医療学会の役割
    　48　ISFP─最新トピックス
    　49　米国Oncofertility Consortium─最新トピックス
    　50　FertiPROTEKT─最新トピックス
    　51　ASCO 2018最新トピックス─妊孕性温存に関する新ガイドライン概要

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 妊孕性温存の基礎

P.9 掲載の参考文献
1. Seisenberger S, Andrews S, Krueger F, et al.:The dynamics of genome-wide DNA methylation reprogramming in mouse primordial germ cells. Mol Cell. 2012;48:849-862.
PubMed
2. Sasaki K, Nakamura T, Okamoto I, et al.:The Germ Cell Fate of Cynomolgus Monkeys Is Specified in the Nascent Amnion. Dev Cell. 2016;39:169-185.
PubMed
3. Sakakibara Y, Hashimoto S, Nakaoka Y, et al.:Bivalent separation into univalents precedes age-related meiosis I errors in oocytes. Nat Commun. 2015;6:7550.
PubMed
4. Gahlay G, Gauthier L, Baibakov B, et al.:Gamete recognition in mice depends on the cleavage status of an egg's zona pellucida protein. Science. 2010;329:216-219.
 
5. Jin M, Fujiwara E, Kakiuchi Y, et al.:Most fertilizing mouse spermatozoa begin their acrosome reaction before contact with the zona pellucida during in vitro fertilization. Proc Natl Acad Sci USA. 2011;108:4892-4896.
PubMed
6. Inoue N, Ikawa M, Isotani A, et al.:The immunoglobulin superfamily protein Izumo is required for sperm to fuse with eggs. Nature. 2005;434:234-238.
PubMed
7. Miyado K, Yoshida K, Yamagata K, et al.:The fusing ability of sperm is bestowed by CD9-containing vesicles released from eggs in mice. Proc Natl Acad Sci USA. 2008;105:12921-12926.
PubMed
8. Bianchi E, Doe B, Goulding D, et al.:Juno is the egg Izumo receptor and is essential for mammalian fertilization. Nature. 2014;508:483-487.
PubMed
9. Ohto U, Ishida H, Krayukuhina E, et al.:Structure of IZUMO1-JUNO reveals sperm-oocyte recognition during mammalian fertilization. Nature. 2016;534:566-569.
 
10. Hayakawa K, Ohgane J, Tanaka S, et al.:Oocyte-specific linker histone H1foo is an epigenomic modulator that decondenses chromatin and impairs pluripotency. Epigenetics. 2012;7:1029-1036.
PubMed
11. Wen D, Banaszynski LA, Liu Y, et al.:Histone variant H3. 3 is an essential maternal factor for oocyte reprogramming. Proc Natl Acad Sci USA. 2014;111:7325-7330.
PubMed
12. Gu TP, Guo F, Yang H, et al.:The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature. 2011;477:606-610.
 
13. Kunitomi A, Yuasa S, Sugiyama F, et al.:H1foo has a pivotal role in qualifying induced pluripotent stem cells. Stem Cell Reports. 2016;6:825-833.
 
14. Hayashi K, Ohta H, Kurimoto K, et al.:Reconstitution of the mouse germ cell specification pathway in culture by pluripotent stem cells. Cell. 2011;146:519-532.
PubMed
15. Irie N, Weinberger L, Tang WW, et al.:SOX17 is a critical specifier of human primordial germ cell fate. Cell. 2015;160:253-268.
PubMed
16. Sasaki K, Yokobayashi S, Nakamura T, et al.:Robust in vitro induction of human germ cell fate from pluripotent stem cells. Cell Stem Cell. 2015;17:178-194.
PubMed
17. Morohaku K, Tanimoto R, Sasaki K, et al.:Complete in vitro generation of fertile oocytes from mouse primordial germ cells. Proc Natl Acad Sci USA. 2016;113:9021-9026.
PubMed
18. Hikabe O, Hamazaki N, Nagamatsu G, et al.:Reconstitution in vitro of the entire cycle of the mouse female germ line. Nature. 2016;539:299-303.
PubMed
19. Yamashiro C, Sasaki K, Yabuta Y, et al.:Generation of human oogonia from induced pluripotent stem cells in vitro. Science. 2018;362:356-360.
PubMed
P.21 掲載の参考文献
1. Neto FT, Bach PV, Najari BB, et al.:Spermatogenesis in humans and its affecting factors. Semin Cell Dev Biol. 2016;59:10-26.
PubMed
2. Misell LM, Holochwost D, Boban D, et al.:A stable isotope-mass spectrometric method for measuring human spermatogenesis kinetics in vivo. J Urol. 2006;175:242-246(discussion 246).
PubMed
3. Amann RP:The cycle of the seminiferous epithelium in humans:a need to revisit? J Androl. 2008;29:469-487.
PubMed
4. Iwamoto T, Nozawa S, Yoshiike M, et al.:Semen quality of 324 fertile Japanese men. Human Reprod. 2006;21:760-765.
PubMed
5. 藤澤正人:I. 男性生殖の基礎知識. 精子形成. 男性不妊症の臨床(岩本晃明, 松田公志編). メジカルビュー社, 2007, pp. 2-9.
 
6. Shiraishi K, Matsuyama H:Gonadotropin actions on spermatogenesis and hormonel therapies for spermatogenenic disorders. Endoc J. 2017;64:123-131.
 
7. 上田秀一, 小沢一史, 河田光博ほか:19章 男性生殖器系. カラーアトラス機能組織学 原著第2版(河田光博, 小路武彦監訳). 医歯薬出版, 2013, pp. 441-467.
 
8. 年森清隆, 伊藤千鶴(訳):22章 男性生殖器系. Ross組織学 原著第5版(内山安男, 相磯貞和監訳). 南江堂, 2010, pp. 728-759.
 
9. 久慈直昭, 上條慎太郎, 井上治ほか:第1章 妊孕性温存の基礎. 02精子の発育. がん・生殖医療妊孕性温存の診療 第1版(鈴木直, 竹原祐志編). 医歯薬出版, 2013, pp. 10-21.
 
10. Conwell CC, Vilfan ID, Hud NV:Controlling the size of nanoscale toroidal DNA condensates with static curvature and ionic strength. Proc Natl Acad Sci USA. 2003;100:9296-9301.
PubMed
P.31 掲載の参考文献
1. Practice Committee of the American Society for Reproductive Medicine:Testing and interpreting measures of ovarian reserve:a committee opinion. Fertil Steril. 2015;103:e9-17.
PubMed
2. Cooper AR, Baker VL, Sterling EW, et al.:The time is now for a new approach to primary ovarian insufficiency. Fertil Steril. 2012;95:1890-1897.
 
3. Lew R.:Natural history of ovarian function including assessment of ovarian reserve and premature ovarian failure. Best Pract Res Clin Obstet Gynaecol. 2019;55:2-13.
PubMed
4. Skinner MK.:Regulation of primordial follicle assembly and development. Hum Reprod Update. 2005;11:461-471.
PubMed
5. Gougeon A.:Regulation of ovarian follicular development in primates:facts and hypotheses. Endocr Rev. 1996;17:121e55.
PubMed
6. Wallace WH, Kelsey TW.:Human ovarian reserve from conception to the menopause. PLoS One. 2010;5:e8772.
 
7. Wang ET, Pisarska MD, Bresee C, et al.:BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertil Steril. 2014;102:1723-1728.
PubMed
8. Gleicher N, Weghofer A, Barad DH.:A pilot study of premature ovarian senescence:I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Mullerian hormone. Fertil Steril. 2009;91:1700-1706.
PubMed
9. Dolleman M, Verschuren WM, Eijkemans MJ, et al.:Reproductive and lifestyle determinants of anti-Mullerian hormone in a large population-based study. J Clin Endocrinol Metab. 2013;98:2106-2115.
 
10. Seyhan A, Ata B, Uncu G.:The impact of endometriosis and its treatment on ovarian reserve. Semin Reprod Med. 2015;33:422-428.
PubMed
11. Loren AW, Mangu PB, Beck LN, et al.:Fertility preservation for patients with cancer:American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500-2510.
 
12. Iwase A, Hirokawa W, Goto M, et al.:Serum anti-Mullerian hormone level is a useful marker for evaluating the impact of laparoscopic cystectomy on ovarian reserve. Fertil Steril. 2010;94:2846-2849.
PubMed
13. Lutchman Singh K, Davies M, Chatterjee R.:Fertility in female cancer survivors:pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update. 2005;11:69-89.
PubMed
14. Teixeira J, Maheswaran S, Donahoe PK.:Mullerian inhibiting substance:an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev. 2001;22:657-674.
PubMed
15. Visser JA, Themmen AP:Anti-Mullerian hormone and folliculogenesis. Mol Cell Endocrinol. 2005;234:81-86.
PubMed
16. Kelsey TW, Wright P, Nelson SM, et al.:A validated model of serum anti-Mullerian hormone from conception to menopause. PLoS One. 2011;6:e22024.
PubMed
17. Bhide P, Pundir J, Homburg R, et al.:Biomarkers of ovarian reserve in childhood and adolescence:A systematic review. Acta Obstet Gynecol Scand. 2019;98:563-572.
PubMed
18. Broer SL, Broekmans FJ, Laven JS, et al.:Anti-Mullerian hormone:ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20:688-701.
PubMed
19. Nelson SM, Pastuszek E, Kloss G, et al.:Two new automated, compared with two enzymelinked immunosorbent, antimullerian hormone assays. Fertil Steril. 2015;104:1016-1021. e6.
 
20. Tal R, Seifer DB:Ovarian reserve testing:a user's guide. Am J Obstet Gynecol. 2017;217:129-140.
 
21. Kwee J, Schats R, McDonnell J, et al.:Intercycle variability of ovarian reserve tests:results of a prospective randomized study. Hum Reprod. 2004;19:590-595.
 
22. Evers JL, Slaats P, Land JA, et al.:Elevated levels of basal estradiol-17beta predict poor response in patients with normal basal levels of follicle-stimulating hormone undergoing in vitro fertilization. Fertil Steril. 1998;69:1010-1014.
PubMed
23. Taylor HS, PAL L, SELI E. (eds):Inhibin, Activin, Follistatin. In:Speroff's Clinical Gynecologic Endocrinology and Infertility 9th edition. Wolters Kluwer, 2019, pp. 145-147.
 
24. Muttukrishna S, McGarrigle H, Wakim R, et al.:Antral follicle count, anti-mullerian hormone and inhibin B:predictors of ovarian response in assisted reproductive technology? BJOG 2005;112:1384-1390.
PubMed
25. McIlveen M, Skull JD, Ledger WL.:Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod. 2007;22:778-785.
 
26. Broer SL, Mol BW, Hendriks D, et al.:The role of antimullerian hormone in prediction of outcome after IVF:comparison with the antral follicle count. Fertil Steril. 2009;91:705-714.
PubMed
27. Broekmans FJ, de Ziegler D, Howles CM, et al.:The antral follicle count:practical recommendations for better standardization. Fertil Steril. 2010;94:1044-1051.
PubMed
28. Lawrenz B, Fehm T, von Wolff M, et al.:Reduced pretreatment ovarian reservein premenopausal female patients with Hodgkin lymphoma or non-Hodgkinlymphoma-evaluation by using anti-Mullerian hormone and retrieved oocytes. Fertil Steril. 2012;98:141-144.
 
29. Phillips KA, Collins IM, Milne RL, et al.:Anti-Mullerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Hum Reprod. 2016;31:1126-1132.
PubMed
30. Senates E, Colak Y, Erdem ED, et al.:Serum anti-Mullerian hormone levels are lower in reproductive-age women with Crohn's disease compared to healthy control women. J Crohns Colitis. 2013;7:e29-34.
PubMed
31. Sonigo C, Beau I, Binart N, et al.:Anti-Mullerian hormone in fertility preservation:clinical and therapeutic applications. Clin Med Insights Reprod Health. 2019;13:1179558119854755.
PubMed
32. Decanter C, Cloquet M, Dassonneville A, et al.:Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy. Reprod Biomed Online. 2018;36:711-718.
PubMed
33. Wallace WH, Smith AG, Kelsey TW, et al.:Fertility preservation for girls and young women with cancer:population-based validation of criteria for ovarian tissue cryopreservation. Lancet Oncol. 2014;15:1129-1136.
 
P.40 掲載の参考文献
1. Mekaru K, Yagi C, Asato K, et al.:Comparison between the gonadotropin-releasing hormone antagonist protocol and the gonadotropin-releasing hormone agonist long protocol for controlled ovarian hyperstimulation in the first in vitro fertilization-embryo transfer cycle in an unspecified of infertile couples. Reprod Med Biol. 2012;11(2):79-83.
 
2. Tang H, Hunter T, Hu Y, et al.:Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2012;2:CD008605.
PubMed
3. Ludwig AK, Glawtz M, Griesinger G, et al.:Perioperative and post-operative complications of transvaginal ultrasound-guided oocyte retrieval:prospective study of >1000 oocyte retrievals. Hum Reprod. 2006;21:3235-3240.
 
4. Dicker D, Ashkenazi J, Feldberg D, et al.:Severe abdominal complications after transvaginal ultrasonographically guided retrieval of oocytes for in vitro fertilization and embryo transfer. Fertil Steril. 1993;59:1313-1315.
PubMed
5. 平原史樹:先天異常モニタリング:我が国と世界の取り組み. 日本産科婦人科学会誌. 2007;59(9):246-250.
 
6. Schreinmachers DM, Cross PK, Hook EB.:Rates of 47, ＋18, 47, ＋18, 47, ＋13, XXY and XXX genotype detected in about 20. 000 prenatal cytogenetic diagnosis by one year maternal age interval. Hum Genet. 1982;61:318-324.
 
7. Bonduelle M, Liebaers I, Deketelaere V, et al.:Neonatal data on a cohort of 2889 infants born after ICSI(1991-1999) and of 2995 infants born after IVF(1983-1999). Human Reprod. 2002;17(3):671-694.
PubMed
8. 三春範夫:染色体異常と男性不妊. HORMONE FRONTIER IN GYNECOLOGY. 2004;11(3):257-263.
Medical*Online
9. Ohashi Y, Miharu N, Honda H, et al.:High frequency of XY disomy in spermatozoa of severe oligozoospermic men. Hum Reprod. 2001;16:703-708.
PubMed
10. Nagafuchi S, Namiki M, Nakahori Y, et al.:A minute deletion of the Y chromosome in men with azoospermia. J Urol. 1993;150(4):1155-1157.
 
P.49 掲載の参考文献
1. Oktay K, Harvey BE, Partridge AH, et al.:Fertility preservation in patients with cancer:ASCO clinical practice guideline update. J Clin Oncol. 2018;36:1994-2001.
PubMed
2. Spears N, Lopes F, Stefansdottir A, et al.:Ovarian damage from chemotherapy and current approaches to its pretection. Hum Reprod Update. 2019;25:673-693.
 
3. Winship AL, Stringer JM, Liew SH, et al.:The importance of DNA repair for maintaining oocyte quality in response to anti-cancer treatments, environmental toxins and maternal ageing. Hum Reprod Update. 2018;24:119-134.
PubMed
4. Sonigo C, Beau I, Binart N, et al.:The impact of chemotherapy on the ovaries:Molecular aspects and the prevention of ovarian damage. Int J Mol Sci. 2019;20:5342.
PubMed
5. Dewailly D, Andersen CY, Balen A, et al.:The physiololgy and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014;20:370-385.
 
6. Kalich-Philosoph L, Roness H, Carmely A, et al.:Cyclophosphamide triggers follicle activation and "burnout";AS101 prevents follicle loss and preserves fertility. Sci Transl Med. 2013;5(185):185ra62.
PubMed
7. Meirow D, Dor J, Kaufman B, et al.:Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod. 2007;22:1626-1633.
PubMed
8. Oktem O, Oktay K:Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer. 2007;110:2222-2229.
PubMed
9. Ben-Aharon I, Bar-Joseph H, Tzarfaty G, et al.:Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol. 2010;8:20.
PubMed
10. Bar-Joseph H, Ben-Aharon I, Tzabari M, et al.:In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLos One. 2011;6:e23492.
PubMed
11. Tsai-Turton M, Luong BT, Tan Y, et al.:Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicol Sci. 2007;98:216-230.
PubMed
12. Devine PJ, Perreault SD, Luderer U:Roles of reactive oxygen species and antioxidants in ovarian toxicity. Biol Reprod. 2012;86:27, 1-10.
 
13. Sonigo C, Beau I, Grynberg M, et al.:AMH prevents primordial ovarian follicle loss and fertility alteration in cyclophosphamide-treated mice. FASEB J. 2019;33:1278-1287.
PubMed
14. Goldman KN, Chenette D, Arju R, et al.:mTORC1/2 inhibitor preserves ovarian function and fertility during genotoxic chemotherapy. Proc Natl Acad Sci USA. 2017;114:3186-3191.
PubMed
15. Zhou L, Xie Y, Li S, et al.:Rapamycin prevents cyclophosphamide-induced over-activation of primordial follicle pool through PI3K/Akt/mTOR signaling pathway in vivo. J. Ovarian Res. 2017;10:56.
 
16. Green DM, Nolan VG, Goodman PJ, et al.:The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure:a report from the Childhood Cancer Suvivor Study. Pediatr Blood Cancer. 2014;61:53-67.
PubMed
17. Bar-Joseph H, Ben-Ahron I, Rizel S, et al.:Doxorubicin-induced apotosis in germinal vesicle (GV) oocytes. Reprod Toxicol. 2010;30:566-572.
 
18. Tanaka Y, Kimura F, Zheng L, et al.:Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model of cisplatin-induced ovarian gonadotoxicity. Exp. Anim. 2018;67:493-500.
 
19. Jang H, Lee OH, Lee Y, et al.:Melatonin prevents cisplatin-induced primordial follicle loss via suppression of PTEN/AKT/FOXO3a pathway activation in the mouse ovary. J Pineal Res. 2016;60:336-347.
 
20. Gonfloni S, Di Tella L, Caldarola S, et al.:Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med. 2009;15:1179-1185.
 
21. Kerr JB, Hutt KJ, Cook M, et al.:Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not preented by imatinib. Nat Med. 2012;18:1170-1172.
 
22. Yucebilgin MS, Terek MC, Ozsaran A, et al.:Effect of chemotherapy on primordial follicular reserve of rat:an animal model of premature ovarian failure and infertility. Aust N Z J Obstet Gynaecol. 2004;44:6-9.
PubMed
23. Tarumi W, Suzuki N, Takahashi N, et al.:Ovarian toxicity of paclitaxel and effect on fertility in the rat. J Obstet Gynecol Res. 2009;35:414-420.
 
24. Zhou WB, Yin H, Liu XA, et al.:Incident of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients. BMC Cancer. 2010;10:281.
PubMed
25. Azem F, Amit A, Merimsky O, et al.:Successful Transfer of frozen-thawed embryos obtained after subtotal colectomy for colorectal cancer and before fluorouracil-based chemotherapy. Gynecol Oncol. 2004;93:263-265.
PubMed
26. Twelves C, Wong A, Nowacki MP, et al.:Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696-2704.
PubMed
27. Ting AY, Petroff BK:Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat. J Assist Reprod Genet. 2010;27:591-597.
 
28. Tsujioka S, Ban Y, Wise LD, et al.:Collaborative work on evaluation of ovarian toxicity. 3)Effects of 2-or 4-week repeated-dose toxicity and fertility studies with tamoxifen in female rats. J Toxicol Sci. 2009;34(Suppl. 1):SP43-SP51.
PubMed
29. Kim SS, Lee JR, Jee BC, et al.:Use of hormonal pretection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol. 2010;53:740-752.
 
30. Abusief ME, Missmer SA, Ginsburg ES, et al.:The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116:791-798.
PubMed
31. Schultheis B, Nijimeijer BA, Yin H, et al.:Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res. 2012;36:271-274.
 
32. Carlsson IB, Laitinen MP, Scott JE, et al.:Kit ligand and c-Kit are expressed during early human ovarian follicular development and their interaction is required for the survival of follicles in long-term culture. Reproduction. 2006;131:641-649.
 
33. U. S. National Library of Medicine (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939b5d1f-9fb2-4499-80ef-0607aa6b114e)
 
34. Loren AW, Mangu PB, Beck LN, et al.:Fertility Preservation for patients with cancer:American Society of Clinical Oncology clinical practice guideline update. 2013;31:2500-2510.
 
35. ISFP Practice Committee, Kim SS, Donnez J, Barri P, et al.:Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet. 2012;29:465-468.
PubMed
36. Zamah AM, Mauro MJ, Druker BJ, et al.:Will imatinib compromise reproductive capacity? Oncologist. 2011;16:1422-1427.
PubMed
P.59 掲載の参考文献
1. 年森清隆, 伊東千鶴:特集 精子をめぐる最新の進歩-精子形成:形態学的・超微形態学的側面. 産婦人科治療. 2008;96:337-344.
 
2. 石川智基, 藤澤正人:特集 精子をめぐる最新の進歩-精巣内局所調節機構. 産婦人科治療. 2008;96:352-356.
 
3. Costabile RA:The effects of cancer and cancer therapy on male reproductive function. J Urol. 1993;149:1327-1330.
PubMed
4. Lee SJ, Schover LR, Partridge AH, et al.:American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917-2931.
 
5. Viviani S, Santoro A, Ragni G, et al.:Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol. 1985;21:601-605.
PubMed
6. Petersen PM, Giwercman A, Skakkebaek NE, et al.:Gonadal function in men with testicular cancer. Semin Oncol. 1998;25:224-233.
PubMed
7. Klein CE:Chapter 46 Gonadal complication and tetratogenicity of cancer therapy. The Chemotherapy Source Book, 3th ed. (eds Perry MC). Lippincott Williams & Wilinks, Philadelphia, 2001, pp. 546-558.
 
8. Loren AW, Mangu PB, Beck LN, et al.:Fertility preservation for patients with cancer:American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500-2510.
 
9. Green DM, Kawashima T, Stovall M, et al.:Fertility of male survivors of childhood cancer:a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010;28:332-339.
PubMed
10. Kenney LB, Laufer MR, Grant FD, et al.:High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001;91:613-621.
PubMed
11. Kumanov P, Nandipati K, Tomova A, et al.:Inhibin B is a better marker of spermatogenesis than other hormones in the evaluation of male factor infertility. Fertil Steril. 2006;86:332-338.
PubMed
12. Ginsberg JP, Ogle SK, Tuchman LK, et al.:Sperm banking for adolescent and young adult cancer patients:sperm quality, patient, and parent perspectives. Pediatr Blood Cancer. 2008;50:594-598.
 
13. Neal MS, Nagel K, Duckworth J, et al.:Effectiveness of sperm banking in adolescents and young adults with cancer:a regional experience. Cancer. 2007;110:1125-1129.
 
14. Hsiao W, Stahl PJ, Osterberg EC, et al.:Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction:The Weill Cornell experience. J Clin Oncol. 2011;29:1607-1611.
PubMed
15. Damani MN, Masters V, Meng MV, et al.:Postchemotherapy ejaculatory azoospermia:fatherhood with sperm from testis tissue with intracytoplasmic sperm injection. J Clin Oncol. 2002;20:930-936.
 
16. Di Santo M, Tarozzi N, Nadalini M, et al.:Human sperm cryopreservation:update on techniques, effect on DNA integrity, and implications for ART. Adv Urol. 2012;2012:854837.
PubMed
17. Woodruff TK and Snyder KA:Oncofertility:Fertility Preservation for Cancer Survivors. 1st ed. Springer, New York, 2007.
 
18. Goossens E, Bilgec T, Van Saen D, et al.:Mouse germ cells go through typical epigenetic modifications after intratesticular tissue grafting. Hum Reprod. 2011;26:3388-3400.
PubMed
19. Sato T, Katagiri K, Gohbara A, et al.:In vitro production of functional sperm in cultured neonatal mouse testes. Nature. 2011;471:504-507.
PubMed
20. Oktay K, Harvey BE, Partridge AH, et al.:Fertility preservation in patients with cancer:ASCO clinical practice guideline update. J Clin Oncol. 2018;36:1994-2001.
PubMed
21. Chow EJ, Kamineni A, Daling JR, et al.:Reproductive outcomes in male childhood cancer survivors:a linked cancer-birth registry analysis. Arch Pediatr Adolesc Med. 2009;163:887-894.
PubMed
22. Madanat-Harjuoja LM, Malila N, Lahteenmaki P, et al.:Risk of cancer among children of cancer patients-a nationwide study in Finland. Int J Cancer. 2010;126:1196-1205.
PubMed
23. Fossa SD, Magelssen H, Melve K, et al.:Parenthood in survivors after adulthood cancer and perinatal health in their offspring:a preliminary report. J Natl Cancer Inst Monogr. 2005;34:77-82.
PubMed
24. Dohle GR:Male infertility in cancer patients:Review of the literature. Int J Urol. 2010;17:327-331.
PubMed
P.66 掲載の参考文献
1. 日本婦人科腫瘍学会(編):子宮頸癌治療ガイドライン2017年版. 金原出版, 2017, p. 47.
 
2. Archana KS, Kanika C, Rajrani S, et al.:Ovarian volume and antral follicle count versus serum FSH measurement in assessment of ovarian reserve. IOSR-JDMS. 2017;16:44-47.
 
3. Wo JY, Viswanathan AN:The impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys. 2009;73:1304-1312.
PubMed
4. Wallace WH, Thomson AB, Kelsey TW:The radiosensitivity of the human oocyte. Hum Reprod. 2003;18:117-121.
PubMed
5. Ogilvy-Stuart AL, Shalet SM.:Effect of radiation on the human reproductive system. Environ Health Perspect. 1993;101:109-116.
PubMed
6. Wallace WH, Thomson AB, Saran F, et al.:Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys. 2005;62:738-744.
PubMed
7. Chemaitilly W, Mertens AC, Mitby P, et al.:Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006;91:1723-1728.
PubMed
8. Loren AW, Mangu PB, Beck LN, et al.:Fertility preservation for patients with cancer:American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500-2510.
 
9. Teh WT, Stern C, Chander S, et al.:The impact of uterine radiation on subsequent fertility and pregnancy outcomes. Biomed Res Int. 2014;2014:482968.
PubMed
10. Dehghan T, Mozdarani H, Khoradmehr A, et al.:Effects of gamma radiation on fetal development in mice. Int J Reprod Biomed(Yazd). 2016;14:247-254.
PubMed
11. Larsen EC, Muller J, Schmiegelow K, et al.:Reduced ovarian function in long-term survivors of radiation-and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab. 2003;88:5307-5314.
 
12. Mahajan N:Fertility preservation in female cancer patients:An overview. J Hum Reprod Sci. 2015;8:3-13.
PubMed
13. Signorello LB, Cohen SS, Bosetti C, et al.:Female survivors of childhood cancer:preterm birth and low birth weight among their children. J Natl Cancer Inst. 2006;98:1453-1461.
 
14. Reulen RC, Zeegers MP, Wallace WH, et al.:Pregnancy outcomes among adult survivors of childhood cancer in the British Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 2009;18:2239-2247.
PubMed
15. Norwitz ER, Stern HM, Grier H, et al.:Placenta percreta and uterine rupture associated with prior whole body radiation therapy. Obstet Gynecol. 2001;98(5 Pt 2):929-931.
 
16. Howell SJ, Shalet SM:Spermatogenesis after cancer treatment:damage and recovery. J Natl Cancer Inst Monogr. 2005;(34):12-17.
 
17. Sanders JE, Hawley J, Levy W, et al.:Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996;87:3045-3052.
 
18. Anserini P, Chiodi S, Spinelli S, et al.:Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. Bone Marrow Transplant. 2002;30:447-451.
PubMed
19. 日本小児内分泌学会(編):小児内分泌学改訂第2版. 診断と治療社, 2016, pp. 223-228.
 
20. 日本小児内分泌学会CCS委員会:小児がん経験者(CCS)のための内分泌フォローアップガイド(2016年7月1日改訂). 日本小児科学会雑誌. 2012;116:1976-1977. (http://jspe.umin.jp/medical/files/guide161006.pdf)
 
21. Chemaitilly W, Li Z, Huang S, et al.:Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy:a report from the St Jude Lifetime Cohort study. J Clin Oncol. 2015;33:492-500.
PubMed
22. Chiarelli AM, Marrett LD, Darlington GA:Pregnancy outcomes in females after treatment for childhood cancer. Epidemiology. 2000;11:161-166.
PubMed
23. Green DM, Whitton JA, Stovall M, et al.:Pregnancy outcome of female survivors of childhood cancer:a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol. 2002;187:1070-1080.
PubMed
24. Green DM, Peabody EM, Nan B, et al.:Pregnancy outcome after treatment for Wilms tumor:a report from the National Wilms Tumor Study Group. J Clin Oncol. 2002;20:2506-2513.
 
25. Green DM, Kawashima T, Stovall M, et al.:Fertility of male survivors of childhood cancer:a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010;28:332-339.
PubMed
26. Green DM, Kawashima T, Stovall M, et al.:Fertility of female survivors of childhood cancer:a report from the childhood cancer survivor study. J Clin Oncol. 2009;27:2677-2685.
PubMed

第2章 妊孕性温存を考慮すべき疾患

P.78 掲載の参考文献
1. 日本がん・生殖医療学会(編):乳がん患者の妊娠・出産と生殖医療に関する診療の手引き2017年版. 金原出版, 2017.
 
2. Hori M, Matsuda T, Shibata A, et al.:Cancer incidence and incidence rates in Japan in 2009:a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan(MCIJ)project. Jpn J Clin Oncol. 2015;45(9):884-891.
PubMed
3. 日本乳癌学会(編):乳癌診療ガイドライン1 治療編2018年版第4版. 金原出版, 2018.
 
4. https://www.oncotypeiq.com/ja-JP/
 
5. Yamauchi H, Nakagawa C, Yamashige S, et al.:Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan. BMC Health Serv Res. 2014;14:372.
PubMed
6. Gianni L, Pienkowski T, Im YH, et al.:Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer(NeoSphere):a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
PubMed
7. von Minckwitz G, Procter M, de Azambuja E, et al.:APHINITY Steering Committee and Investigators.:Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377:122-131.
 
8. Yamauchi H, Okawa M, Yokoyama S, et al.:High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound:findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan. Breast Cancer Res Treat. 2018;172(3):679-687.
PubMed
9. Schmid P, Adams S, Rugo HS, et al., for the IMpassion130 Trial Investigators:Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):108-2121.
 
10. https://jbcrg.jp/clinicaltrials/698/
 
11. Halpern N, Sonnenblick A, Uziely B, et al.:Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer. Int J Cancer. 2017;140:2145-2149.
PubMed
12. Clarke M, Collins R, Darby S, et al., Early Breast Cancer Trialists' Collaborative Group(EBCTCG):Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomised trials. Lancet. 2005;366(9503):2087-2106.
 
13. Masuda N, Lee SJ, Ohtani S, et al.:Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147-2159.
PubMed
14. Kataoka A, Tokunaga E, Masuda N, et al.:Clinicopathological features of young patients(<35 years of age)with breast cancer in a Japanese Breast Cancer Society supported study. Breast Cancer. 2014;21(6):643-650.
PubMed
15. Kataoka A, Iwamoto T, Tokunaga E, et al.:Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors:a study from the Japanese Breast Cancer Registry. Breast Cancer Res Treat. 2016;160(1):163-172.
 
16. Oktay K, Harvey BE, Partridge AH, et al.:Fertility preservation in patients with cancer:ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(19):1994-2001.
 
17. Lambertini M, Kroman N, Ameye L, et al.:Long-term safety of pregnancy following breast cancer according to estrogen receptor status. J Natl Cancer Inst. 2018;110(4):426-429.
PubMed
18. Pan H, Gray R, Braybrooke J, et al.:20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836-1846.
 
19. https://jbcrg.jp/en/clinicaltrials/1160/
 
P.86 掲載の参考文献
1. 国立がん研究センター・がん情報サービス「地域がん登録全国合計によるがん罹患データ」(https://ganjoho.jp/reg_stat/statistics/dl/index.html#incidence4pref)
 
2. 国立がん研究センター・がん情報サービス「小児・AYA 世代のがん罹患データ(2009～2011年)」(https://ganjoho.jp/reg_stat/statistics/dl/index.html#childhoodAYA)
 
3. 日本血液学会(編):造血器腫瘍診療ガイドライン2018年版. 金原出版, 2018.
 
4. NCCN Guideline Acute Myeloid Leukemia Ver3. 2020.
 
5. 梅澤佳史, 川又紀彦:ゲノム異常に基づいたAML新規治療. 臨床血液. 2019;60:594-599.
 
6. 村田誠:急性リンパ性白血病に対する抗体医薬の臨床効果. 医学のあゆみ. 2019;268:49-53.
Medical*Online
7. Mahon FX, Rea D, Guilhot J, et al.:Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years:the prospective, multicentre Stop Imatinib(STIM) trial. Lancet Oncol. 2010;11:1029-1035.
PubMed
8. Imagawa J, Tanaka H, Okada M, et al.:Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year(DADI trial:a multicentre phase 2 trial. Lancet Haematol. 2015;2(12):e528-535.
 
9. Vassilakopoulos TP, Chatzidimitriou C, Asimakopoulos JV, et al.:Immunotherapy in Hodgkin Lymphoma:Present Status and Future Strategies. Cancers(Basel). 2019;11(8):1071.
PubMed
10. Leung W, Hudson MM, Strickland DK, et al.:Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol. 2000;18:3273-3279.
PubMed
11. Branvall E, Derolf AR, Johansson E, et al.:Self-reported fertility in long-term survivors of acute myeloid leukemia. Ann Hematol. 2014;93:1491-1498.
PubMed
12. Seshadri T, Hourigan MJ, Wolf M, et al.;The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function. Leuk Res. 2006;30:483-485.
PubMed
13. 日本癌治療学会(編):小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン2017年版. 金原出版, 2017.
 
14. Hodgson DC, Pintilie M, Gitterman L, et al.:Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol. 2007;25:11-15.
PubMed
15. Paoli D, Rizzo F, Fiore G, et al.:Spermatogenesis in Hodgkin's lymphoma patients:a retrospective study of semen quality before and after different chemotherapy regimens. Hum Reprod. 2016;31:263-272.
PubMed
16. Behringer K, Mueller H, Goergen H, et al.:Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013;31:231-239.
 
17. Elis A, Tevet A, Yerushalmi R, et al.:Fertility status among women treated for aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2006;47:623-627.
PubMed
18. Gharwan H, Lai C, Grant C, et al.:Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas. Leuk Lymphoma. 2016;57:1616-1624.
PubMed
19. Meissner J, Tichy D, Katzke V, et al.:Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma. Ann Oncol. 2015;6:1771-1776.
PubMed
P.95 掲載の参考文献
1. 日本泌尿器科学会・日本病理学会・日本医学放射線学会・日本臨床腫瘍学会(編):精巣腫瘍取扱い規約第4版. 金原出版, 2018.
 
2. Moch H, Cubilla AL, Humphrey PA, et al.:The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A:Renal, Penile, and Testicular Tumours. Eur Urol. 2016;70(1):93-105.
 
3. 日本泌尿器科学会(編):精巣腫瘍診療ガイドライン2015年版. 金原出版, 2015.
 
4. Oechsle K, Lorch A, Honecker F, et al.:Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor. Oncology. 2010;78(1):47-53.
PubMed
5. Heidenreich A, Pfister D, Witthuhn R, et al.:Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer:radical or modified template resection. Eur Urol. 2009;55(1):217-224.
PubMed
6. Williams DH 4th, Karpman E, Sander JC, et al.:Pretreatment semen parameters in men with cancer. J Urol. 2009;181(2):736-740.
 
7. Moody JA, Ahmed K, Horsfield C, et al.:Fertility preservation in testicular cancer-predictors of spermatogenesis. BJU Int. 2018;122(2):236-242.
PubMed
8. Ostrowski KA, Walsh TJ:Infertility with Testicular Cancer. Urol Clin North Am. 2015;42(3):409-420.
PubMed
9. Skakkebaek NE, Rajpert-De Meyts E, Main KM:Testicular dysgenesis syndrome:an increasingly common developmental disorder with environmental aspects. Hum Reprod. 2001;16(5):972-978.
PubMed
10. Walsh TJ, Croughan MS, Schembri M, et al.:Increased risk of testicular germ cell cancer among infertile men. Arch Intern Med. 2009;169(4):351-356.
PubMed
11. Jacobsen R, Bostofte E, Engholm G, et al.:Risk of testicular cancer in men with abnormal semen characteristics:cohort study. BMJ. 2000;321(7264):789-792.
PubMed
12. Doria-Rose VP, Biggs ML, Weiss NS:Subfertility and the risk of testicular germ cell tumors(United States). Cancer Causes Control. 2005;16(6):651-656.
PubMed
13. Nakamura T, Kawauchi A, Oishi M, et al.:Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors. Int J Clin Oncol. 2016;21(4):791-795.
PubMed
14. Pont J, Albrecht W, Postner G, et al.:Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer:long-term results of a prospective trial. J Clin Oncol. 1996;14(2):441-448.
 
15. Gospodarowicz M:Testicular cancer patients:considerations in long-term follow-up. Hematol Oncol Clin North Am. 2008;22(2):245-255, vi.
PubMed
16. Spermon JR, Ramos L, Wetzels AM, et al.:Sperm integrity pre-and post-chemotherapy in men with testicular germ cell cancer. Hum Reprod. 2006;21(7):1781-1786.
PubMed
17. Howell SJ, Shalet SM:Spermatogenesis after cancer treatment:damage and recovery. J Natl Cancer Inst Monogr. 2005;(34):12-17.
 
P.101 掲載の参考文献
1. 日本小児血液・がん学会:疾患登録集計結果 (https://www.jspho.jp/disease_record.html)
 
2. 国立がん研究センターがん情報サービスがん登録・統計 (https://ganjoho.jp/reg_stat/statistics/stat/summary.html)
 
3. Katanoda K, Shibata A, Matsuda T, et al.:Childhood, adolescent and young adult cancer incidence in Japan in 2009-2011. Jpn J Clin Oncol 2017;47:762-771.
 
4. Chichra A, Mahajan A:Recent advances in childhood cancer;Fifty years of progress. Apollo Med. 2012;9(2):140-145.
 
5. Oktay K, Harvey BE, Partridge AH, et al.:Fertility Preservation in Patients With Cancer:ASCO Clinical Practice Guideline. J Clin Oncol. 2018;36(19):1994-2001.
 
6. Metzger ML, Meacham LR, Patterson B, et al.:Female reproductive health after childhood, adolescent, and young adult cancers:guidelines for the assessment and management of female reproductive complications. J Clin Oncol. 2013;31(9):1239-1247.
 
7. Kenney LB, Cohen LE, Shnorhavorian M, et al.:Male reproductive health after childhood, adolescent, and young adult cancers:a report from the Children's Oncology Group. J Clin Oncol. 2012;30(27):3408-3416.
 
8. Anderson RA, Mitchell RT, Kelsey TW, et al.:Cancer treatment and gonadal function:experimental and established strategies for fertility preservation in children and young adults. Lancet Diabetes Endocrinol. 2015;3(7):556-567.
 
9. Meirow D, Ra'anani H, Shapira M, et al.:Transplantations of frozen-thawed ovarian tissue demonstrate high reproductive erformance and the need to revise restrictive criteria. Fertil Steril. 2016;106(2):467-474.
 
10. Hwang JH, Yoo HJ, Park SH, et al.:Association between the location of transposed ovary and ovarian function in patients with uterine cervical cancer treated with(postoperative or primary) pelvic radiotherapy. Fertil Steril. 2012;97(6):1387-1393.
PubMed
11. Meirow D, Levron J, Eldar-Geva T, et al.:Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med. 2005;353(3):318-321.
 
P.106 掲載の参考文献
1. Brouwer J, Hazes JM, Laven JS, et al.:Fertility in women with rheumatoid arthritis:Influence of disease activity and medication. Ann Rheum Dis. 2015;74:1836-1841.
PubMed
2. Danchenko N, Satia JA, Anthony MS:Epidemiology of systemic lupus erythematosus:A comparison of worldwide disease burden. Lupus. 2006;15:308-318.
PubMed
3. 難病情報センター:全身性エリテマトーデス(SLE)(指定難病49). (http://www.nanbyou.or.jp/entry/215)
 
4. Fanouriakis A, Kostopoulou M, Alunno A, et al.:2019 Update of the eular recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736-745.
PubMed
5. 厚生労働科学研究費補助金難治性疾患等政策研究事業自己免疫疾患に関する研究班(自己免疫班), 日本リウマチ学会(編):全身性エリテマトーデス診療ガイドライン2019. 南山堂, 2019.
 
6. Andreoli L, Bertsias GK, Agmon-Levin N, et al.:Eular recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76:476-485.
PubMed
7. Flint J, Panchal S, Hurrell A, et al.:Bsr and Bhpr guideline on prescribing drugs in preg nancy and breastfeeding-Part I:Standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology(Oxford). 2016;55:1693-1697.
 
8. Tomimitsu H, Ohta A, Nagai M, et al.:Epidemiologic analysis of the clinical features of Japanese patients with polymyositis and dermatomyositis. Mod Rheumatol. 2016;26:398-402.
PubMed
9. Kohsaka H, Mimori T, Kanda T, et al.:Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Mod Rheumatol. 2019;29:1-19.
PubMed
10. Tsuji H, Nakashima R, Hosono Y, et al.:A multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2019 Sep. 16. doi:10.1002/art.41105.
 
11. 厚生労働省難治性疾患政策研究事業難治性血管炎に関する調査研究班, 日本循環学会・他(編):血管炎症候群の診療ガイドライン(2017年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2017_isobe_h.pdf)
 
12. Nakano N, Mori M, Umebayashi H, et al.:Characteristics and outcome of intractable vasculitis syndrome in children:Nation-wide survey in Japan. Mod Rheumatol. 2018;28:697-702.
PubMed
13. Mok CC, Lau CS, Wong RW:Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998;41:831-837.
PubMed
14. Boumpas DT, Austin HA 3rd, Vaughan EM, et al.:Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993;119:366-369.
PubMed
15. Ioannidis JP, Katsifis GE, Tzioufas AG, et al.:Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol. 2002;29:2129-2135.
PubMed
16. Elizur SE, Chian RC, Pineau CA, et al.:Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents. Rheumatology(Oxford). 2008;47:1506-1509.
PubMed
17. Henes M, Henes JC, Neunhoeffer E, et al.:Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy:Experiences from the Ferti-PROTEKT network. Lupus. 2012;21:953-958.
 
18. Andreoli L, Crisafulli F, Tincani A:Pregnancy and reproductive aspects of systemic lupus erythematosus. Curr Opin Rheumatol. 2017;29:473-479.
PubMed
19. Chehab G, Krussel J, Fehm T, et al.:Successful conception in a 34-year-old lupus patient following spontaneous pregnancy after autotransplantation of cryopreserved ovarian tissue. Lupus. 2019;28:675-680.
 
20. Van Assche G, Dignass A, Reinisch W, et al.:The second European evidence-based consensus on the diagnosis and management of Crohn's disease:Special situations. J Crohns Colitis. 2010;4:63-101.
PubMed
P.116 掲載の参考文献
1. Fletcher CD, Hogendoorn P, Mertens F, et al.:WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. IARC Press, 2013.
 
2. 日本整形外科学会骨軟部腫瘍委員会/国立がん研究センター(編):平成25年度全国骨腫瘍登録一覧表. 2013.
 
3. 日本整形外科学会骨軟部腫瘍委員会/国立がん研究センター(編):平成25年度全国軟部腫瘍登録一覧表. 2013.
 
4. Ogura K, Higashi T, Kawai A:Statistics of bone sarcoma in Japan:Report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci. 2017;22(1):133-143.
PubMed
5. Ogura K, Higashi T, Kawai A:Statistics of soft-tissue sarcoma in Japan:Report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci. 2017;22(4):755-764.
PubMed
6. Gurney JG, Swensen AR, Bulterys M:Malignant Bone Tumors. In:Cancer Incidence and Survival among Children and Adolescents:United States SEER Program 1975-1999(ed. by Ries LAG, Smith MA, Gurney JG, et al.). National Cancer Institute, SEER Program. NIH Pub, 1999.
 
7. Amin MB, Edge SB, Greene FL, et al. (eds.):AJCC Cancer Staging Manual, 8th ed. Springer-Verlag, 2017.
 
8. Sheth DS, Yasko AW, Raymond AK, et al.:Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome. Cancer. 1996;78(10):2136-2145.
PubMed
9. Grimer RJ, Bielack S, Flege S, et al.:Periosteal osteosarcoma-a European review of outcome. Eur J Cancer. 2005;41(18):2806-2811.
PubMed
10. Kurt AM, Unni KK, McLeod RA, et al.:Low-grade intraosseous osteosarcoma. Cancer. 1990;65(6):1418-1428.
PubMed
11. Link MP, Goorin AM, Horowitz M, et al.:Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res. 1991;(270):8-14.
PubMed
12. Souhami RL, Craft AW, Van der Eijken JW, et al.:Randomised trial of two regimens of chemotherapy in operable osteosarcoma:a study of the European Osteosarcoma Intergroup. Lancet. 1997;350(9082):911-917.
PubMed
13. Goorin AM, Schwartzentruber DJ, Devidas M, et al.:Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma:Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21(8):1574-1580.
 
14. Meyers PA, Schwartz CL, Krailo M, et al.:Osteosarcoma:a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and highdose methotrexate. J Clin Oncol. 2005;23(9):2004-2011.
 
15. Bielack SS, Smeland S, Whelan JS, et al.:Methotrexate, doxorubicin, and cisplatin(MAP)plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP:First results of the EURAMOS-1 Good Response Randomized Controlled Trial. J Clin Oncol. 2015;33(20):2279-2287.
PubMed
16. Harris MB, Gieser P, Goorin AM, et al.:Treatment of metastatic osteosarcoma at diagnosis:a Pediatric Oncology Group Study. J Clin Oncol. 1998;16(11):3641-3648.
 
17. Kager L, Zoubek A, Potschger U, et al.:Primary metastatic osteosarcoma:presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21(10):2011-2018.
 
18. Harris MB, Cantor AB, Goorin AM, et al.:Treatment of osteosarcoma with ifosfamide:comparison of response in pediatric patients with recurrent disease versus patients previously untreated:a Pediatric Oncology Group study. Med Pediatr Oncol. 1995;24(2):87-92.
 
19. Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al.:Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone:a long-term follow-up of the First Intergroup study. J Clin Oncol. 1990;8(10):1664-1674.
 
20. Burgert EO Jr, Nesbit ME, Garnsey LA, et al.:Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone:intergroup study IESS-II. J Clin Oncol. 1990;8(9):1514-1524.
 
21. Evans RG, Nesbit ME, Gehan EA, et al.:Multimodal therapy for the management of local ized Ewing's sarcoma of pelvic and sacral bones:a report from the second intergroup study. J Clin Oncol. 1991;9(7):1173-1180.
 
22. Miser JS, Kinsella TJ, Triche TJ, et al.:Ifosfamide with mesna uroprotection and etoposide:an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987;5(8):1191-1198.
 
23. Grier HE, Krailo MD, Tarbell NJ, et al.:Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694-701.
 
24. Womer RB, West DC, Krailo MD, et al.:Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma:a report from the Children's Oncology Group. J Clin Oncol. 2012;30(33):4148-4154.
 
25. Pervaiz N, Colterjohn N, Farrokhyar F, et al.:A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573-581.
PubMed
26. Kataoka K, Tanaka K, Mizusawa J, et al.:A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for highgrade soft tissue sarcoma:Japan Clinical Oncology Group Study JCOG1306. Jpn J Clin Oncol. 2014;44(8):765-769.
 
P.128 掲載の参考文献
1. 日本食道学会(編):食道癌診療ガイドライン2017年版. 金原出版, 2017.
 
2. 日本胃癌学会(編):胃癌治療ガイドライン2017年1月改訂第5版. 金原出版, 2018.
 
3. 大腸癌研究会(編):大腸癌治療ガイドライン2019年版. 金原出版, 2019.
 
4. 日本肝臓学会(編):肝癌診療ガイドライン2017年版. 金原出版, 2017 年.
 
5. 日本膵臓学会膵癌診療ガイドライン改訂委員会(編):膵癌診療ガイドライン2019年版. 金原出版, 2019.
 
6. Yuan Zeng, Wenli Ruan, Jun Liu, et al.:Esophageal cancer in patients under 50:a SEER analysis. J Thorac Dis. 2018;10:2542-2550.
PubMed
7. 伊藤公訓, 北村正輔, 松尾泰直ほか:若年者胃癌の特徴. 中高年に認める胃癌との相違. 若年者胃癌のリスク. 胃と腸. 2011;46(9):1325-1332.
 
8. Fidler MM, Gupta S, Soerjomataram I, et al.:Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012:a population-based study. Lancet Oncol. 2017;18:1579-1589.
PubMed
9. Maureen E, Mork Y, Nancy You, et al.:High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. J Clin Oncol. 2015;33:3544-3549.
 
10. Chang PE, Ong WC, Lui HF, et al.:Is the prognosis of young patients with hepatocellular carcinoma poorer than the prognosis of older patient? A comparative analysis of clinical characteristics, prognostic features, and survival outcome. J Gastroenterol. 1008;43:881-888.
 
11. Primavesi F, Stattner S, Schlick K, et al.:Pancreatic cancer in young adults:changes, challenges, and solutions. Onco Targets Ther. 2019;12:3387-3400.
PubMed
12. Kang JS, Jang JY, Kwon W, et al.:Clinicopathologic and survival differences in younger patients with pancreatic ductal adenocarcinoma-A propensity score-matched comparative analysis. Pancreatology. 2017;17:827-832.
PubMed
P.136 掲載の参考文献
1. Brain Tumor Registry of Japan(2005-2008). Neurol Med Chir(Tokyo). 2017;57(Suppl. 1):9-102.
 
2. Nakamura H, Makino K, Yano S, et al.:Epidemiological study of primary intracranial tumors:a regional survey in Kumamoto prefecture in southern Japan-20-year study. Int J Clin Oncol. 2011;16:314-321.
PubMed
3. Ostrom QT, Cioffi G, Gittleman H, et al.:CBTRUS statistical report:primary brain and other central nervous system tumors diagnose in the United States in 2012-2016. Neuro Oncol. 2019;21(Suppl. 5):v1-v100.
 
4. International Agency for Research on Cancer:WHO Classification of Tumours of the Central Nervous System, Revised. 4th ed. Louis DN, Ohgaki H, Wiestler OD, et al. (eds.)(WHO Classification of Tumours, Vol. 1). World Health Organization, 2016.
 
5. 日本脳腫瘍学会(編):脳腫瘍診療ガイドライン2019年版, 成人脳腫瘍編. 金原出版, 2019.
 
6. Buckner JC, Shaw EG, Pugh SL, et al.:Radiation plus procarbazine, CCNU, and vinc tine in low-grade glioma. N Engl J Med. 2016;374:1344-1355.
 
7. Collins VP, Jones DT, Giannini C:Pilocytic astrocytoma:pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129:775-788.
PubMed
8. Northcott PA, Robinson GW, Kratz CP, et al.:Medulloblastoma. Nat Rev Dis Primers. 2019;5:11.
PubMed
9. 松谷雅生:脳腫瘍治療学. 金芳堂, 2016, pp. 449-440.
 
P.144 掲載の参考文献
1. Espenschied CR, LaDuca H, Li S, et al.:Multigene Panel Testing Provides a New Perspective on Lynch Syndrome. J Clin Oncol. 2017;35:2568-2575.
PubMed
2. LaDuca H, Polley EC, Yussuf A, et al.:A clinical guide to hereditary cancer panel testing:evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165, 000 high-risk patients. Genet Med. 2019 Aug 13. doi:10.1038/s41436-019-0633-8.
 
3. Jonsson P, Bandlamudi C, Cheng ML, et al.:Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019;571:576-579.
PubMed
4. Golan T, Hammel P, Reni M, et al.:Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317-327.
PubMed
5. Hussain M, Mateo J, Fizazi K, et al.:PROfound:Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer(mCRPC) with homologous recombination repair(HRR) gene alterations. ESMO 2019 congress, LBA12_PR (https://oncologypro.esmo.org/Meeting-Resources/ESMO-2019-Congress)
 
6. Latham A, Srinivasan P, Kemel Y, et al.:Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol. 2019;37:286-295.
 
7. 日本癌治療学会/日本臨床腫瘍学会(編):成人・小児進行固形がんにおける臓器横断的ゲノム診療のガイドライン第2版, 金原出版, 2019.
 
8. Momozawa Y, Iwasaki Y, Parsons MT, et al.:Germline pathogenic variants of 11 breast cancer genes in 7, 051 Japanese patients and 11, 241 controls. Nat Commun. 2018;9:4083.
PubMed
9. Enomoto T, Aoki D, Hattori K, et al.:The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer:CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA(CHARLOTTE). Int J Gynecol Cancer. 2019;29:1043-1049.
PubMed
10. Kiyozumi Y, Matsubayashi H, Horiuchi Y, et al.:Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients. Cancer Med. 2019;8:5534-5543.
PubMed
11. Takahashi K, Sato N, Sugawara T, et al.:Clinical characteristics of Lynch-like cases collaterally classified by Lynch syndrome identification strategy using universal screening in endometrial cancer. Gynecol Oncol. 2017;147:388-395.
PubMed
12. 大腸癌研究会(編):遺伝性大腸癌診療ガイドライン2016年版. 金原出版, 2016.
 
13. Copson ER, Maishman TC, Tapper WJ, et al.:Germline BRCA mutation and outcome in young-onset breast cancer(POSH):a prospective cohort study. Lancet Oncol. 2018;19:169-180.
 
14. Carter NJ, Marshall ML, Susswein LR, et al.:Germline pathogenic variants identified in women with ovarian tumors. Gynecol Oncol. 2018;151:481-488.
PubMed
15. Song H, Cicek MS, Dicks E, et al.:The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 2014;23:4703-4709.
PubMed
16. Sugawara T, Sato N, Shimizu D, et al.:Efficient screening strategy for Lynch syndrome in Japanese endometrial cancer. Tohoku J Exp Med. 2015;235:117-125.
PubMed
17. He Y, Tao X, Huang F, et al.:Clinicopathologic features of endometrial cancer in Chinese patients younger than 50 years with a family history of cancer. Medicine(Baltimore). 2018;97:e12968.
 
18. Pearlman R, Frankel WL, Swanson B, et al.:Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol. 2017;3:464-471.
PubMed
19. Stoffel EM, Koeppe E, Everett J, et al.:Germline genetic features of young individuals with colorectal cancer. Gastroenterology. 2018;154:897-905.
PubMed
20. Mauri G, Sartore-Bianchi A, Russo AG, et al.:Early-onset colorectal cancer in young individuals. Mol Oncol. 2019;13:109-131.
PubMed
21. Mork ME, You YN, Ying J, et al.:High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. J Clin Oncol. 2015;33:3544-3549.
 
22. Ring KL, Bruegl AS, Allen BA, et al.:Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. Mod Pathol. 2016;29:1381-1389.
 
23. Morii-Kashima M, Tsubamoto H, Sato C, et al.:Development of an integrated support system for hereditary cancer and its impact on gynecologic services. Int J Clin Oncol. 2014;19:1043-1051.
 
24. Ueda M, Tsubamoto H, Kashima-Morii M, et al.:Challenges in managing patients with hereditary cancer at gynecological services. Obstet Gynecol Int. 2019;2019:4365754.
 
25. 鹿嶋見奈, 鍔本浩志, 上田真子ほか:遺伝性腫瘍女性3症例の妊孕性温存に対して認定遺伝カウンセラー(R)が果たした役割. 日本遺伝カウンセリング学会誌. 2019;40:115-119.
Medical*Online
26. Lin W, Titus S, Moy F, et al.:Ovarian aging in women with BRCA germline mutations. J Clin Endocrinol Metab. 2017;102(10):3839-3847.
PubMed
27. Lambertini M, Goldrat O, Ferreira AR, et al.:Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2018;29(1):237-243.
PubMed
28. Peccatori FA, Mangili G, Bergamini A, et al.:Fertility preservation in women harboring deleterious BRCA mutations:ready for prime time? Hum Reprod. 2018;33:181-187.
PubMed
29. 認定遺伝カウンセラー制度委員会Webページ (http://plaza.umin.ac.jp/~GC/index.html)
 
30. Marton I, Vranes HS, Sparac V, et al.:Two cases of successful pregnancies after hysteroscopic removal of endometrioid adenocarcinoma gradeI, stageIA, in young women with Lynch syndrome. J Turk Ger Gynecol Assoc. 2014;15:63-66.
 
31. Falcone F, Laurelli G, Losito S, et al.:Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol. 2017;28:e2.
PubMed
32. Moller P, Seppala TT, Bernstein I, et al.:Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age:a report from the Prospective Lynch Syndrome Database. Gut. 2018;67:1306-1316.
PubMed
33. Woolderink JM, De Bock GH, de Hullu JA, et al.:Characteristics of Lynch syndrome associated ovarian cancer. Gynecol Oncol. 2018;150:324-330.
PubMed
34. Tan MH, Mester JL, Ngeow J, et al.:Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18:400-407.
PubMed
35. Kalin A, Merideth MA, Regier DS, et al.:Management of reproductive health in Cowden syndrome complicated by endometrial polyps and breast cancer. Obstet Gynecol. 2013;121:461-464.
PubMed
36. Morse CB, Garcia RL, Calhoun KE, et al.:Premalignant alterations in breast and endometrium associated with a PTEN mutation in a woman with Cowden syndrome:implications for preventive care. Gynecol Oncol Rep. 2015;12:13-16.
 
37. Schmeler KM, Daniels MS, Brandt AC, et al.:Endometrial cancer in an adolescent:a possible manifestation of Cowden syndrome. Obstet Gynecol. 2009;114:477-479.
 
38. Edwards JM, Alsop S, Modesitt SC:Coexisting atypical polypoid adenomyoma and endometrioid endometrial carcinoma in a young woman with Cowden syndrome:Case report and implications for screening and prevention. Gynecol Oncol Case Rep. 2012;2:29-31.
 
39. Baker WD, Soisson AP, Dodson MK:Endometrial cancer in a 14-year-old girl with Cowden syndrome:a case report. J Obstet Gynaecol Res. 2013;39:876-878.
 
P.155 掲載の参考文献
1. 国立がん研究センターがん情報サービス:地域がん登録全国推計によるがん罹患データ(1993-2014年)(がんに関する統計データのダウンロード https://ganjoho.jp/reg_stat/statistics/dl/index.html)
 
2. 日本産科婦人科学会:婦人科腫瘍委員会報告 (http://www.jsog.or.jp/modules/committee/index.php?content_id=7)
 
3. 日本婦人科腫瘍学会(編):卵巣がん治療ガイドライン2015年版. 金原出版, 2015, pp. 65-67.
 
4. 厚生労働省:人口動態統計月報年計(概数)の概況 (https://www.mhlw.go.jp/toukei/list/81-1a.html)
 
5. 日本婦人科腫瘍学会(編):卵巣がん治療ガイドライン2015年版. 金原出版, 2015, pp. 56-64.
 
6. Harter P, Sehouli J, Lorusso D, et al.:A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380:822-832.
PubMed
7. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer(Version 4. 2017). NCCN Clinical Practice Guidelines in Oncology. 2019. (https://www2.tri-kobe.org/nccn/guideline/gynecological/english/ovarian.pdf)
 
8. 日本婦人科腫瘍学会(編):卵巣がん治療ガイドライン2015年版. 金原出版, 2015, pp. 78-99.
 
9. 日本婦人科腫瘍学会(編):卵巣がん治療ガイドライン2015年版. 金原出版, 2015, pp. 28-29, p. 54.
 
10. Burger RA, Brady MF, Bookman MA, et al., for the Gynecologic Oncology Group:Incor poration of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-2483.
 
11. Perren TJ, Swart AM, Pfisterer J, et al.:ICON7 Investigators:A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-2496.
 
12. 日本婦人科腫瘍学会(編):卵巣がん治療ガイドライン2015年版. 金原出版, 2015, pp. 65-67.
 
13. Morice P, Joulie F, Camatte S, et al.:Lymph node involvement in epithelial ovarian cancer:analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg. 2003;197:198-205.
PubMed
14. Morice P, Denschlag D, Rodolakis A, et al.:Fertility Task Force of the European Society of Gynecologic Oncology:Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. Int J Gynecol Cancer. 2011;21:951-963.
PubMed
15. Cho YH, Kim DY, Kim JH, et al.:Is complete surgical staging necessary in patients with stageI mucinous epithelial ovarian tumors? Gynecol Oncol. 2006;103:878-882.
 
16. Benjamin I, Morgan MA, Rubin SC.:Occult bilateral involvement in stageI epithelial ovarian cancer. Gynecol Oncol. 1999;72:288-291.
 
17. Marpeau O, Schilder J, Zafrani Y, et al.:Prognosis of patients who relapse after fertility-sparing surgery in epithelial ovarian cancer. Ann Surg Oncol. 2008;15:478-483.
PubMed
18. Lee SJ, Schover LR, Partridge AH, et al.:American Society of Clinical Oncology:American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917-2931.
 
19. Loren AW, Mangu PB, Beck LN, et al.:American Society of Clinical Oncology:Fertility preservation for patients with cancer:American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500-2510.
 
20. Satoh T, Hatae M, Watanabe Y, et al.:Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer:a proposal for patient selection. J Clin Oncol. 2010;28:1727-1732.
 
21. Park JY, Kim DY, Suh DS, et al.:Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer:oncologic safety and reproductive outcomes. Gynecol Oncol. 2008;110:345-353.
PubMed
22. Fruscio R, Corso S, Ceppi L, et al.:Conservative management of early-stage epithelial ovarian cancer:results of a large retrospective series. Ann Oncol. 2013;24:138-144.
PubMed
23. Zanetta G, Chiari S, Rota S, et al.:Conservative surgery for stageI ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol. 1997;104:1030-1035.
 
24. Schilder JM, Thompson AM, DePriest PD, et al.:Outcome of reproductive age women with stageIA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002;87:1-7.
PubMed
25. Morice P, Leblanc E, Rey A, et al.:GCCLCC and SFOG:Conservative treatment in epithelial ovarian cancer:results of a multicentre study of the GCCLCC(Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG(Societe Francaise d'Oncologie Gynecologique). Hum Reprod. 2005;20:1379-1385.
PubMed
26. Schlaerth AC, Chi DS, Poynor EA, et al.:Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19:1199-1204.
 
27. Anchezar JP, Sardi J, Soderini A:Long-term follow-up results of fertility sparing surgery in patients with epithelial ovarian cancer. J Surg Oncol. 2009;100:55-58.
PubMed
28. Kajiyama H, Shibata K, Suzuki S, et al.:Fertility-sparing surgery in young women with invasive epithelial ovarian cancer. Eur J Surg Oncol. 2010;36:404-408.
PubMed
29. Ditto A, Martinelli F, Lorusso D, et al.:Fertility sparing surgery in early stage epithelial ovarian cancer. J Gynecol Oncol. 2014;25:320-327.
PubMed
30. Jiang X, Yang J, Yu M, et al.:Oncofertility in patients with stageI epithelial ovarian cancer:fertility-sparing surgery in young women of reproductive age. World J Surg Oncol. 2017;15:154.
 
31. Kajiyama H, Shibata K, Mizuno M, et al.:Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. Br J Cancer. 2011;105:1288-1294.
PubMed
32. Fruscio R, Ceppi L, Corso S, et al.:Long-term results of fertility-sparing treatment com pared with standard radical surgery for early-stage epithelial ovarian cancer. Br J Cancer. 2016;115:641-648.
 
33. Satoh T, Tsuda H, Kanato K, et al.:Gynecologic Cancer Study Group of the Japan Clinical Oncology Group:A non-randomized confirmatory study regarding selection of fertility-sparing surgery for patients with epithelial ovarian cancer:Japan Clinical Oncology Group Study(JCOG1203). Jpn J Clin Oncol. 2015;45:595-599.
 
34. Kuchenbaecker KB, Hopper JL, Barnes DR, et al.:Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317:2402-2416.
PubMed
35. Genetic/Familial High-Risk Assessment:Breast and Ovarian(Version 3. 2019). NCCN Clinical Practice Guidelines in Oncology. (https://www2.tri-kobe.org/nccn/guideline/gynecological/english/genetic_familial.pdf)
 
36. Rebbeck TR, Kauff ND, Domchek SM:Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80-87.
PubMed
37. Eisen A, Lubinski J, Klijn J, et al.:Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers:an international case-control study. J Clin Oncol. 2005;23:7491-7496.
PubMed
38. Domchek SM, Friebel TM, Singer CF, et al.:Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967-975.
PubMed
39. Finch AP, Lubinski J, Moller P, et al.:Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32:1547-1553.
PubMed
40. Titus S, Li F, Stobezki R, et al.:Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5:172ra21.
PubMed
41. Hermsen BB, Olivier RI, Verheijen RH, et al.:No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers;an observational follow-up study. Br J Cancer. 2007;96:1335-1342.
PubMed
42. Henderson JT, Webber EM, Sawaya GF:Screening for ovarian cancer:Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319:595-606.
PubMed
43. Iodice S, Barile M, Rotmensz N, et al.:Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers:a meta-analysis. Eur J Cancer. 2010;46:2275-2284.
PubMed
44. Cibula D, Zikan M, Dusek L, et al.:Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers:a meta-analysis. Expert Rev Anticancer Ther. 2011;11:1197-1207.
PubMed
P.165 掲載の参考文献
1. Munoz N, Franceschi S, Bosetti C, et al.:Role of parity and human papillomavirus in cervical cancer:the IARC multicentric case-control study. Lancet. 2002;359:1093-1101.
PubMed
2. Moreno V, Bosch FX, Munoz N, et al.:Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection:the IARC multicentric case-control study. Lancet. 2002;359:1085-1092.
PubMed
3. Appleby P, Beral V, Berrington de Gonzalez A, et al.:Carcinoma of the cervix and tobacco smoking:collaborative reanalysis of individual data on 13, 541 women with carcinoma of the cervix and 23, 017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118:1481-1495.
PubMed
4. Yagi A, Ueda Y, Kakuda M, et al.:Epidemiological and clinical analyses of cervical cancer using data from the population-based Osaka cancer registry. Cancer Res. 2019;79(6):1252-1259.
 
5. Ferlay J, Soerjomataram I, Ervik M, et al. (ed.):GLOBOCAN 2012:Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 v1. 0. IARC CancerBase No. 11. 2012.
 
6. Morris M, Eifel PJ, Lu J, et al.:Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for highrisk cervical cancer. N Engl J Med. 1999;340:1137-1143.
PubMed
7. Rose PG, Bundy BN, Watkins EB, et al.:Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144-1153.
PubMed
8. Whitney CW, Sause W, Bundy BN, et al.:Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage II B-IV A carcinoma of the cervix with negative para-aortic lymph nodes:a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339-1348.
 
9. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al.:Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606-1613.
PubMed
P.174 掲載の参考文献
1. 榎本隆之:日本産科婦人科学会婦人科腫瘍委員会報告. 2017年度患者年報. 日本産科婦人科学会雑誌. 2019;64:669-802.
 
2. Galaal K, Bryant A, Fisher AD, et al.:Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev. 2012 Sep. 12;(9):CD006655.
 
3. He H, Zeng D, Ou H, et al.:Laparoscopic treatment of endometrial cancer:systematic review. J Minim Invasive Gynecol. 2013;20(4):413-23.
PubMed
4. Chiou HY, Chiu LH, Chen CH, et al.:Comparing robotic surgery with laparoscopy and laparotomy for endometrial cancer management:a cohort study. Int J Surg. 2015;13:17-22.
PubMed
5. Coronado PJ, Herraiz MA, Magrina JF, et al.:Comparison of perioperative outcomes and cost of robotic-assisted laparoscopy, laparoscopy and laparotomy for endometrial cancer. Eur J Obstet Gynecol Reprod Biol. 2012;165(2):289-294.
PubMed
6. 日本婦人科腫瘍学会(編):子宮体がん治療ガイドライン2018年版. 金原出版, 2018.
 
7. 日本産科婦人科内視鏡学会(編):産婦人科内視鏡手術ガイドライン2019年版. 金原出版, 2019.
 
8. Phelippeau J, Koskas M:Impact of Radical Hysterectomy on Survival in Patients with Stage 2 Type1 Endometrial Carcinoma:A Matched Cohort Study. Ann Surg Oncol. 2016;23(13):4361-4367.
PubMed
9. Boronow RC, Morrow CP, Creasman WT, et al.:Surgical staging in endometrial cancer:clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984;63(6):825-832.
PubMed
10. Chi DS, Barakat RR, Palayekar MJ, et al.:The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer. 2008;18(2):269-273.
PubMed
11. Mariani A, Dowdy SC, Cliby WA, et al.:Prospective assessment of lymphatic dissemination in endometrial cancer:a paradigm shift in surgical staging. Gynecol Oncol. 2008;109(1):11-18.
PubMed
12. ASTEC study group, Kitchener H, Swart AM, Qian Q, et al.:Efficacy of systematic pelvic lymphadenectomy in endometrial cancer(MRC ASTEC trial):a randomised study. Lancet. 2009;373(9658):125-136.
 
13. Benedetti Panici P, Basile S, Maneschi F, et al.:Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma:randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707-1716.
PubMed
14. Todo Y, Kato H, Kaneuchi M, et al.:Survival effect of para-aortic lymphadenectomy in endometrial cancer(SEPAL study):a retrospective cohort analysis. Lancet. 2010;375(9721):1165-1172.
PubMed
15. Eggemann H, Ignatov T, Kaiser K, et al.:J Cancer Res Clin Oncol. 2016;142(5):1051-1060.
PubMed
16. Randall ME, Filiaci VL, Muss H, et al.;Gynecologic Oncology Group Study:J Clin Oncol. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma:a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24(1):36-44.
 
17. Nomura H, Aoki D, Michimae H, et al.;Japanese Gynecologic Oncology Group:Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression:A randomized clinical trial. JAMA Oncol. 2019;5(6):833-840.
 
18. Le DT, Uram JN, Wang H, et al.:PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-2520.
PubMed
19. Marabelle A, Le DT, Ascierto PA, et al.:Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer:Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1-10.
PubMed
P.184 掲載の参考文献
1. 厚生省心身障害研究(武谷班):リプロダクティブヘルスからみた子宮内膜症の実態と対策に関する研究. 平成9年度研究報告書, 1998.
 
2. 大須賀穣:子宮内膜症の病因・病態をめぐって 内分泌学的・免疫学的アプローチから. 日本産科婦人科学会雑誌. 2012;64:105-111.
 
3. Osuga Y, Koga K, Hirota Y, et al.:Lymphocytes in endometriosis. Am J Reprod Immunol. 2011;65:1-10.
PubMed
4. Kobayashi H, Sumimoto K, Moniwa N, et al.:Risk of developing ovarian cancer among women with ovarian endometrioma:a cohort study in Shizuoka, Japan. Int J Gynecol Cancer. 2007;17:37-43.
PubMed
5. Doody MC, Gibbons WE, Buttram VC, Jr.:Linear regression analysis of ultrasound follicular growth series:evidence for an abnormality of follicular growth in endometriosis patients. Fertil Steril. 1988;49:47-51.
PubMed
6. Tummon IS, Maclin VM, Radwanska E, et al.:Occult ovulatory dysfunction in women with minimal endometriosis or unexplained infertility. Fertil Steril. 1988;50:716-720.
PubMed
7. Saito H, Seino T, Kaneko T, et al.:Endometriosis and oocyte quality. Gynecol Obstet Invest. 2002;53:46-51.
PubMed
8. Toya M, Saito H, Ohta N, et al.:Moderate and severe endometriosis is associated with alterations in the cell cycle of granulosa cells in patients undergoing in vitro fertilization and embryo transfer. Fertil Steril. 2000;73:344-350.
PubMed
9. Nakahara K, Sakai N, Saito H, et al.:Incidence of apoptotic bodies in membrana granulosa of the patients participating in an in vitro fertilization program. Fertil Steril. 1997;67:302-308.
 
10. Seino T, Saito H, Kaneko T, et al.:Eight-hydroxy-2'-deoxyguanosine in granulosa cells is correlated with the quality of oocytes and embryos in an in vitro fertilization-embryo transfer program. Fertil Steril. 2002;77:1184-1190.
 
11. Lachapelle MH, Hemmings R, Roy DC, et al.:Flow cytometric evaluation of leukocyte subpopulations in the follicular fluids of infertile patients. Fertil Steril. 1996;65:1135-1140.
PubMed
12. Garrido N, Navarro J, Remohi J, et al.:Follicular hormonal environment and embryo quality in women with endometriosis. Hum Reprod Update. 2000;6:67-74.
PubMed
13. Pellicer A, Albert C, Mercader A, et al.:The follicular and endocrine environment in women with endometriosis:Local and systemic cytokine production. Fertil Steril. 1998;70:425-431.
PubMed
14. Wunder D, Mueller M, Birkhauser M, et al.:Increased ENA-78 in the follicular fluid of patients with endometriosis. Acta Obstet Gynecol Scand. 2006;85:336-342.
PubMed
15. Lo Turco EG, Souza GHMF, Garcia JS et al.:Effect of endometriosis on the protein expression pattern of follicular fluid from patients submitted to controlled ovarian hyperstimulation for in vitro fertilization. Human Reproduction. 2010;25:1755-1766.
PubMed
16. Gupta S, Goldberg JM, Aziz N, et al.:Pathogenic mechanisms in endometriosis-associated infertility. Fertil Steril. 2008;90:247-257.
PubMed
17. Cahill DJ, Wardle PG, Maile LA, et al.:Pituitary-ovarian dysfunction as a cause for endometriosis-associated and unexplained infertility. Human Reproduction. 1995;10:3142-3146.
PubMed
18. Tsoumpou I, Kyrgiou M, Gelbaya TA, et al.:The effect of surgical treatment for endometrioma on in vitro fertilization outcomes:a systematic review and meta-analysis. Fertil Steril. 2009;92:75-87.
PubMed
19. Somigliana E, Infantino M, Benedetti F, et al.:The presence of ovarian endometriomas is associated with a reduced responsiveness to gonadotropins. Fertil Steril. 2006;86:192-196.
PubMed
20. Benaglia L, Somigliana E, Vercellini P, et al.:Endometriotic ovarian cysts negatively affect the rate of spontaneous ovulation. Hum Reprod. 2009;24:2183-2186.
PubMed
21. Kitajima M, Defrere S, Dolmans M-M, et al.:Endometriomas as a possible cause of reduced ovarian reserve in women with endometriosis. Fertil Steril. 2011;96:685-691.
PubMed
22. Beretta P, Franchi M, Ghezzi F, et al.:Randomized clinical trial of two laparoscopic treatments of endometriomas:cystectomy versus drainage and coagulation. Fertil Steril. 1998;70:1176-1180.
PubMed
23. Busacca M, Riparini J, Somigliana E, et al.:Postsurgical ovarian failure after laparoscopic excision of bilateral endometriomas. Am J Obstet Gynecol. 2006;195:421-425.
PubMed
24. Iwase A, Hirokawa W, Goto M, et al.:Serum anti-Mullerian hormone level is a useful marker for evaluating the impact of laparoscopic cystectomy on ovarian reserve. Fertil Steril. 2010;94:2846-2849.
PubMed
25. Somigliana E, Benaglia L, Vercellini P, et al.:Recurrent endometrioma and ovarian reserve:biological connection or surgical paradox? Am J Obstet Gynecol. 2011;204(6):529. e1-5.
PubMed
26. Koga K, Takemura Y, Osuga Y, et al.:Recurrence of ovarian endometrioma after laparoscopic excision. Hum Reprod. 2006;21:2171-2174.
PubMed
27. Takamura M, Koga K, Osuga Y, et al.:Post-operative oral contraceptive use reduces the risk of ovarian endometrioma recurrence after laparoscopic excision. Hum Reprod. 2009;24(12):3042-3048.
PubMed
28. Seracchioli R, Mabrouk M, Frasca C, et al.:Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence:a randomized controlled trial. Fertil Steril. 2010;93:52-56.
PubMed
29. Vercellini P, Eskenazi B, Consonni D, et al.:Oral contraceptives and risk of endometriosis:a systematic review and meta-analysis. Hum Reprod Update. 2011;17(2):159-170.
PubMed
30. Somigliana E, Vigano P, Filippi F, et al.:Fertility preservation in women with endometriosis:for all, for some, for none? Hum Reprod. 2015;30(6):1280-1286.
PubMed
31. Jacobson TZ, Duffy JM, Barlow D, et al.:Laparoscopic surgery for subfertility associated with endometriosis. Cochrane Database Syst Rev. CD001398, 2010.
PubMed
32. The Practice Committee of the American Society for Reproductive Medicine:Endometriosis and infertility:a committee opinion. Fertil Steril. 2012;98:591-598.
PubMed
33. Guo Y-h, Lu N, Zhang Y, et al.:Comparative study on the pregnancy outcomes of in vitro fertilization-embryo transfer between long-acting gonadotropin-releasing hormone agonist combined with transvaginal ultrasound-guided cyst aspiration and long-acting gonadotropin-releasing hormone agonist alone. Contemporary Clinical Trials. 2012;33:1206-1210.
PubMed

第3章 妊孕性温存療法の実際

P.196 掲載の参考文献
1. 日本産科婦人科学会 登録・調査小委員会:ARTデータブック2017年 (http://plaza.umin.ac.jp/~jsog-art/)
 
2. Whittingham DG:Survival of mouse embryos after freezing and thawing. Nature. 1971;233(5315):125-126.
PubMed
3. Whittingham DG, Leibo SP, Mazur P.:Survival of mouse embryos frozen to -196 degrees and -269 degrees C. Science. 1972;178(4059):411-414.
PubMed
4. Trounson A, Mohr L:Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature. 1983;305(5936):707-709.
PubMed
5. Chen C:Pregnancy after human oocyte cryopreservation. Lancet. 1986;1(8486):884-886.
PubMed
6. Rall WF, Fahy GM:Ice-free cryopreservation of mouse embryos at -196 degrees C by vitrification. Nature. 1985;313(6003):573-575.
PubMed
7. Kuleshova L, Gianaroli L, Magli C, et al.:Birth following vitrification of a small number of human oocytes:case report. Hum Reprod. 1999;14(12):3077-3079.
PubMed
8. Cobo A, Diaz C:Clinical application of oocyte vitrification:a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2011;96(2):277-285.
PubMed
9. Cil AP, Bang H, Oktay K:Age-specific probability of live birth with oocyte cryopreservation:an individual patient data meta-analysis. Fertil Steril. 2013;100(2):492-499. e493.
 
10. Shaw JM, Kuleshova LL, MacFarlane DR, et al.:Vitrification properties of solutions of ethylene glycol in saline containing PVP, Ficoll, or dextran. Cryobiology. 1997;35(3):219-229.
PubMed
11. Mori C, Yabuuchi A, Ezoe K, et al.:Hydroxypropyl cellulose as an option for supplementation of cryoprotectant solutions for embryo vitrification in human assisted reproductive technologies. Reprod Biomed Online. 2015;30(6):613-621.
PubMed
12. Levine J, Canada A, Stern CJ:Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4831-4841.
 
13. Practice Committees of American Society for Reproductive Medicine;Society for Assisted Reproductive Technology:Mature oocyte cryopreservation:a guideline. Fertil Steril. 2013;99(1):37-43.
PubMed
14. Loren AW, Mangu PB, Beck LN, et al.:Fertility preservation for patients with cancer:American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500-2510.
 
15. 日本産科婦人科学会:医学的適応による未受精卵子, 胚(受精卵)および卵巣組織の凍結・保存に関する見解. 日本産科婦人科学会雑誌. 2019;71(5):609-611.
 
16. Ajala T, Rafi J, Larsen-Disney P, et al.:Fertility preservation for cancer patients:a review. Obstet Gynecol Int. 2010;2010:160386.
 
P.205 掲載の参考文献
1. Whittingham DG, Leibo SP MP:Survival of mouse embryos frozen to -196 degrees and -269 degrees C. Science. 1972;178:411-414.
 
2. Trounson A, Mohr L:Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature. 1983;305:707-709.
PubMed
3. Rall WF, Fahy GM:Ice-free cryopreservation of mouse embryos at -196 degrees C by vitrification. Nature. 1985;313:573-575.
PubMed
4. Kasai M, Komi JH, Takakamo A, at al.:A simple method for mouse embryo cryopreservation in a low toxicity vitrification solution, without appreciable loss of viability. J Reprod Fertil. 1990;89:91-97.
 
5. Kuwayama M, Hamano S, Nagai T:Vitrification of bovine blastocysts obtained by in vitro culture of oocytes matured and fertilized in vitro. J Reprod Fertil. 1992;96:187-193.
PubMed
6. 日本産科婦人科学会ホームページ:(https://plaza.umin.ac.jp/~jsog-art/2017data_20191015.pdf)
 
7. Ethics Committee of the American Society for Reproductive Medicine:Fertility preservation and reproduction in cancer patients. Fertil Steril. 2005;83:1622-1628.
 
8. Lee SJ, Schover LR, Partridge AH, et al.:American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917-2931.
 
9. Von Wolff M, Montag M, Dittrich R, et al.:Fertility preservation in women-A practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network Ferti-PROTEKT. Arch Gynecol Obstet. 2011;284(2):427-435.
 
10. Rienzi L, Gracia C, Maggiulli R, et al.:Oocyte, embryo and blastocyst cryopreservation in ART:systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2017;23:139-155.
PubMed
11. Benifla JL, Letur-Konirsch H, Collin G, et al.:Safety of cryopreservation straws for human gametes or embryos:a preliminary study with human immunodeficiency virus-1 deficiency virus-1. Hum Reprod. 2000;15:2186-2189.
 
12. Kuleshova LL, Shaw JM:A strategy for rapid cooling of mouse embryos within a double straw to eliminate the risk of contamination during storage in liquid nitrogen. Hum Reprod. 2000;15:2604-2609.
PubMed
13. Bielanski A, Bergeron H, Lau PCK, et al.:Microbial contamination of embryos and semen during long term banking in liquid nitrogen. Cryobiology. 2003;46:146-152.
PubMed
14. Molina I, Mari M, Martinez JV, et al.:Bacterial and fungal contamination risks in human oocyte and embryo cryopreservation:open versus closed vitrification systems. Fertil Steril. 2016;106:127-132.
PubMed
15. Youm HS, Choi JR, Oh D, et al.:Closed versus open vitrification for human blastocyst cryopreservation:A meta-analysis. Cryobiology. 2017;77:64-70.
PubMed
16. Pantos K, Athanasiou V, Stefanidis K, et al.:Influence of advanced age on the blastocyst development rate and pregnancy rate in assisted reproductive technology. Fertil Steril. 1999;71:1144-1146.
PubMed
17. Ata B, Kaplan B, Danzer H, et al.:Array CGH analysis shows that aneuploidy is not related to the number of embryos generated. Reprod Biomed Online. 2012;24:614-620.
PubMed
18. Toftager M, Bogstad J, Bryndorf T, et al.:Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol:RCT including 1050 first IVF/ICSI cycles. Hum Reprod. 2016;31:1253-1264.
PubMed
19. Cheung LP, Lam PM, Lok IH, et al.:GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF:A randomized controlled trial. Hum Reprod. 2005;20:616-621.
PubMed
20. Oktay K, Hourvitz A, Sahin G, et al.:Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91:3885-3890.
PubMed
21. Oktay K, Turan V, Bedoschi G, et al.:Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol. 2015;33:2424-2429.
PubMed
22. Goldrat O, Gervy C, Englert Y, et al.:Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients. Hum Reprod. 2015;30:2184-2189.
PubMed
23. Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA:GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online. 2010;20:783-788.
PubMed
24. Cakmak H, Katz A, Cedars MI, et al.:Effective method for emergency fertility preservation:Random-start controlled ovarian stimulation. Fertil Steril. 2013;100:1673-1680.
PubMed
25. Qin N, Chen Q, Hong Q, et al.:Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection. Fertil Steril. 2016;106:334-341. e1.
 
26. Kuang Y, Chen Q, Hong Q, et al.:Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes(Shanghai protocol). Reprod Biomed Online. 2014;29:684-691.
 
27. Ubaldi FM, Capalbo A, Vaiarelli A, et al.:Follicular versus luteal phase ovarian stimulation during the same menstrual cycle(DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate:new insight in ovarian reserve exploitation. Fertil Steril. 2016;105:1488-1495. e1. 28.
 
28. Chen Q, Wang Y, Sun L, et al.:Controlled ovulation of the dominant follicle using progestin in minimal stimulation in poor responders. Reprod Biol Endocrinol. 2017;15:71.
 
29. Massin N:New stimulation regimens:Endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017;23:211-220.
PubMed
30. Xiao ZN, Peng JL, Yang J, et al.:Flexible GnRH antagonist protocol versus progestin-primed ovarian stimulation(PPOS) protocol in patients with polycystic ovary syndrome:Comparison of clinical outcomes and ovarian response. Curr Med Sci. 2019;39:431-436.
PubMed
31. Engmann L, DiLuigi A, Schmidt D, et al.:The use of gonadotropin-releasing hormone(GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome:a prospective randomized controlled study. Fertil Steril. 2008;89:84-91.
PubMed
32. Geva E, Jaffe RB:Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril. 2000;74:429-438.
PubMed
33. Albert C, Garrido N, Mercader A, et al.:The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod. 2002;8:409-418.
PubMed
34. Mourad S, Brown J, Farquhar C:Interventions for the prevention of OHSS in ART cycles:An overview of Cochrane reviews. Cochrane Database Syst Rev. 2017 Jan. 23;1:CD012103. doi:10.1002/14651858.CD012103.pub2.
 
35. Ferrero H, Garcia-Pascual CM, Gomez R, et al.:Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro:Implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists. Fertil Steril. 2014;102(5):1468-1476. e1.
 
36. Cullinan-Bove K, Koos RD:Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus:rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology. 1993;133:829-837.
PubMed
37. Shrem G, Steiner N, Balayla J, et al.:Use of cabergoline and post-collection GnRH antagonist administration for prevention of ovarian hyperstimulation syndrome. Reprod Biomed Online. 2019;39:433-438.
PubMed
38. Grynberg M, Poulain M, Le Parco S:Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients. Hum Reprod. 2016;31:623-629.
PubMed
39. Wisanto A, Bollen N, Camus M, et al.:Effect of transuterine puncture during transvaginal oocyte retrieval on the results of human in vitro fertilization. Hum Reprod. 1989;4:790-793.
 
40. Prasath EB, Chan MLH, Wong WHW, et al.:First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient. Hum Reprod. 2014;29:276-278.
 
41. Kim SK, Kim MS, Kim H, et al.:Mature oocyte retrieval during laparotomic debulking surgery following random-start controlled ovarian stimulation for fertility preservation in a patient with suspected ovarian cancer. Obstet Gynecol Sci. 2015;58:537.
 
42. Ito A, Katagiri Y, Fukuda Y, et al.:Ultrasound-guided laparotomic oocyte retrieval during surgery for fertility preservation in a case of tumor recurrence after a unilateral salpingo-oophorectomy. Reprod Med Biol. 2018;17:98-102.
 
P.215 掲載の参考文献
1. Christianson MS, Oktay K:Advances in fertility-preservation surgery:navigating new frontiers. Fertil Steril. 2019;112:438-445.
PubMed
2. Donnez J, Dolmans MM, Demylle D, et al.:Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405-1410.
PubMed
3. Gellert SE, Pors SE, Kristensen SG, et al.:Transplantation of frozen-thawed ovarian tissue:an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Reprod Genet. 2018;35:561-570.
PubMed
4. Donnez J, Dolmans MM:Fertility preservation in women. N Engl J Med. 2017;377:1657-1665.
PubMed
5. Practice Committee of the American Society for Reproductive Medicine:Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy:a committee opinion. Fertil Steril. 2019;112(6):1022-1033.
 
6. von Wolff M, Montag M, Dittrich R, et al.:Fertility preservation in women-a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet. 2011;284:427-435.
PubMed
7. Waimey KE, Duncan FE, Su HI, et al.:Future directions in oncofertility and fertility preservation:A report from the 2011 oncofertility consortium conference. J Adolesc Young Adult Oncol. 2013;2(1):25-30.
PubMed
8. Furui T, Takenaka M, Makino H, et al.:An evaluation of the Gifu Model in a trial for a new regional oncofertility network in Japan, focusing on its necessity and effects. Reprod Med Biol. 2016;15(2):107-113.
 
9. Roness H, Meirow D:Follicle reserve loss in ovarian tissue transplantation. Reproduction. 2019 Aug. 1. pii:REP-19-0097. R2. doi:10.1530/REP-19-0097.
 
10. Leonel E, Lucci CM, Amorim CA:Cryopreservation of human ovarian tissue:A review. Transfus Med Hemoth. 2019;46:173-181.
 
11. Gook DA, Edgar DH, Stern C:Effect of cooling rate and dehydration regimen on the his tological appearance of human ovarian cortex following cryopreservation in 1, 2-propanediol. Hum Reprod. 1999;14:2061-2068.
 
12. Amorim C, David A, Langendonckt A, et al.:Vitrification of human ovarian tissue:effect of different solutions and procedures. Fertil Steril. 2011;95:1094-1097.
PubMed
13. Lee S, Ryu KJ, Kim B, et al.:Comparison between slow freezing and vitrification for human ovarian tissue cryopreservation and xenotransplantation. Int J Mol Sci. 2019;20:3346.
PubMed
14. Shi Q, Xie Y, Wang Y, et al.:Vitrification versus slow freezing for human ovarian tissue cryopreservation:a systematic review and meta-anlaysis. Sci Rep. 2017;7:8538.
PubMed
15. Dolmans MM, Marinescu C, Saussoy P, et al.:Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010;116:2908-2914.
PubMed
16. Greve T, Clasen-Linde E, Andersen MT, et al.:Cryopreserved ovarian cortex from patients with leukemia in complete remission contains no apparent viable malignant cells. Blood. 2012;120:4311-4316.
PubMed
17. Shapira M, Raanani H, Barshack I, et al.:First delivery in a leukemia survivor after transplantation of cryopreserved ovarian tissue, evaluated for leukemia cells contamination. Fertil Steril. 2018;109:48-53.
 
18. Silber SJ, DeRosa M, Goldsmith S, et al.:Cryopreservation and transplantation of ovarian tissue:results from one center in the USA. J Assist Reprod Genet. 2018;35:2205-2213.
PubMed
19. Amorim CA, David A, Dolmans MM, et al.:Impact of freezing and thawing of human ovarian tissue on follicular growth after long-term xenotransplantation. J Assist Reprod Genet. 2011;28:1157-1165.
PubMed
20. Siebzehnrubl E, Kohl J, Dittrich R et al.:Freezing of human ovarian tissue-not the oocytes but the granulosa is the problem. Mol Cell Endocrinol. 2000;169:109-111.
PubMed
21. Corral A, Clavero M, Gallardo M, et al.:Ovarian tissue cryopreservation by stepped vitrification and monitored by X-ray computed tomography. Cryobiology. 2018;81:17-26.
PubMed
22. Gallardo M, Paulini F, Corral A, et al.;Evaluation of a new freezing protocol containing 20% dimethyl sulphoxide concentration to cryopreserve human ovarian tissue. Reprod Biomed Online. 2018;37:653-665.
PubMed
23. Maffei S, Pennarossa G, Brevini TAL et al.:Beneficial effect of directional freezing on in vitro viability of cryopreserved sheep whole ovaries and ovarian cortical slices. Hum Reprod. 2014;29:114-124.
PubMed
24. Song YS, Adler D, Xu F, et al.:Vitrification and levitation of a liquid droplet on liquid nitrogen. Proc Natl Acad Sci USA. 2010;107:4596-4600.
PubMed
25. Seveus, L:Preparation of biological material for X-ray microanalysis of diffusible elements. J Microsc. 1978;112:269-279.
PubMed
26. Barbato V, Gualtieri R, Capriglione T, et al.:Slush nitrogen vitrification of human ovarian tissue does not alter gene expression and improves follicle health and progression in longterm in vitro culture. Fertil Steril. 2018;110:1356-1366.
 
27. Talevi R, Barbato V, Fiorentino I, et al.:Successful slush nitrogen vitrification of human ovarian tissue. Fertil Steril. 2016;105:1523-1531. e1.
 
P.225 掲載の参考文献
1. 日本産科婦人科学会:施設一覧 (http://www.jsog.or.jp/facility_program/search_result_facility.php)
 
2. Beckmann MW, Lotz L, Toth B, et al.:Concept paper on the technique of cryopreservation, removal and transplantation of ovarian tissue for fertility preservation. Geburtshilfe Frauenheilkd 2019;79(1):53-62.
PubMed
3. Poirot C, Abirached F, Prades M, et al.:Induction of puberty by autograft of cryopreserved ovarian tissue. Lancet. 2012;379(9815):588.
PubMed
4. Andersen CY, Kristensen SG:Novel use of the ovarian follicular pool to postpone menopause and delay osteoporosis. Reprod Biomed Online. 2015;31(2):128-131.
PubMed
5. von Wolff M, Stute P, Fluck C:Autologous transplantation of cryopreserved ovarian tissue to induce puberty-the endocrinologists' view. Eur J Pediatr. 2016;175(12):2007-2010.
PubMed
6. Jensen AK, Kristensen SG, Macklon KT, et al.:Outcomes of transplantations of cryopreserved ovarian tissue to 41 women in Denmark. Hum Reprod. 2015;30(12):2838-2845.
PubMed
7. Oktay K, Harvey BE, Partridge AH, et al.:Fertility preservation in patients with cancer:ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994-2001.
 
8. Yasmin E, Balachandren N, Davies MC, et al.;British Fertility Society:Fertility preservation for medical reasons in girls and women:British fertility society policy and practice guideline. Hum Fertil(Camb). 2018;21(1):3-26.
 
9. Suzuki N:Clinical practice guidelines for fertility preservation in pediatric, adolescent, and young adults with cancer. Int J Clin Oncol. 2019;24(1):20-27.
 
10. Practice Committee of the American Society for Reproductive Medicine:Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy:a committee opinion. Fertil Steril. 2019;112(6):1022-1033.
 
11. Blumenfeld Z:Ovarian tissue transplantation and leukemia. Fertil Steril. 2018;109(1):69-70.
PubMed
12. Shenfield F, de Mouzon J, Scaravelli G, et al.:Oocyte and ovarian tisse cryopreservation in European countries:statutory background, practice, storage and use. Human Reproduction Open. 2017;2017(1):hox003.
 
13. Sanada Y, Harada M, Kunitomi C, et al.:A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients. J Obstet Gynaecol Res. 2019;45(10):2021-2028.
PubMed
14. von Wolff M, Andersen CY, Woodruff TK, et al.:FertiPROTEKT, Oncofertility Consortium and the Danish Fertility-Preservation Networks-What Can We Learn From Their Experiences? Clin Med Insights:Reprod Health. 2019;13:1179558119845865.
PubMed
15. Donnez J, Dolmans MM:Fertility preservation in women. N Engl J Med. 2017;377(17):1657-1665.
PubMed
16. Gellert SE, Pors SE, Kristensen SG, et al.:Transplantation of frozen-thawed ovarian tissue:an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Reprod Genet. 2018;35(4):561-570.
PubMed
17. Pacheco F, Oktay K:Current success and efficiency of autologous ovarian transplantation:A meta-analysis. Reprod Sci. 2017;24(8):1111-1120.
PubMed
18. Donnez J, Dolmans MM, Demylle D, et al.:Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405-1410.
PubMed
19. Jensen AK, Macklon KT, Fedder J, et al.:86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue:focus on birth and perinatal outcome in 40 of these children. J Assist Reprod Genet. 2017;34(3):325-336.
 
20. Lotz L, Dittrich R, Hoffmann I, et al.:Ovarian tissue transplantation:Experience from Germany and worldwide efficacy. Clin Med Insights Reprod Health. 2019;13:1179558119867357.
PubMed
21. von Wolff M, Germeyer A, Liebenthron J, et al.:Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part II:fertility preservation techniques. Arch Gynecol Obstet. 2018;297(1):257-267.
PubMed
22. Beckmann MW, Dittrich R, Lotz L, et al.:Fertility protection:complications of surgery and results of removal and transplantation of ovarian tissue. Reprod Biomed Online. 2018;36(2):188-196.
PubMed
23. Beckmann MW, Dittrich R, Lotz L, et al.:Operative techniques and complications of extraction and transplantation of ovarian tissue:the Erlangen experience. Arch Gynecol Obstet. 2017;295(4):1033-1039.
PubMed
24. Ladanyi C, Mor A, Christianson MS, et al.:Recent advances in the field of ovarian tissue cryopreservation and opportunities for research. J Assist Reprod Genet. 2017;34(6):709-722.
 
25. Dolmans MM, Marinescu C, Saussoy P, et al.:Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010;116(16):2908-2914.
PubMed
26. Van der Ven H, Liebenthron J, Beckmann M, et al.:Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network:tissue activity, pregnancy and delivery rates. Hum Reprod. 2016;31(9):2031-2041.
 
27. Donnez J, Dolmans MM:Ovarian cortex transplantation:60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice. J Assist Reprod Genet. 2015;32(8):1167-1170.
PubMed
28. Shapira M, Raanani H, Barshack I, et al.:First delivery in a leukemia survivor after transplantation of cryopreserved ovarian tissue, evaluated for leukemia cells contamination. Fertil Steril. 2018;109(1):48-53.
 
29. Dolmans MM, Luyckx V, Donnez J, et al.:Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertil Steril. 2013;99(6):1514-1522.
PubMed
30. Masciangelo R, Bosisio C, Donnez J, et al.:Safety of ovarian tissue transplantation in patients with borderline ovarian tumors. Hum Reprod. 2018;33(2):212-219.
PubMed
31. Takae S, Suzuki N:Current state and future possibilities of ovarian tissue transplantation. Reprod Med Biol, 2019;18(3):217-224.
PubMed
32. Baird DT, Webb R, Campbell BK, et al.:Long-term ovarian function in sheep after ovariectomy and transplantation of autografts stored at-196 C. Endocrinology. 1999;140(1):462-471.
PubMed
33. Shikanov A, Zhang Z, Xu M, et al.:Fibrin encapsulation and vascular endothelial growth factor delivery promotes ovarian graft survival in mice. Tissue Eng Part A. 2011;17(23-24):3095-3104.
 
34. Kalogeris T, Baines CP, Krenz M, et al.:Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol. 2012;298:229-317.
PubMed
35. Gao JM, Yan J, Li R, et al.:Improvement in the quality of heterotopic allotransplanted mouse ovarian tissues with basic fibroblast growth factor and fibrin hydrogel. Hum Reprod. 2013;28(10):2784-2793.
 
36. Neulen J, Yan Z, Raczek S, et al.:Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells:importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 1995;80(6):1967-1971.
PubMed
37. Christenson LK, Stouffer RL:Follicle-stimulating hormone and luteinizing hormone/chorionic gonadotropin stimulation of vascular endothelial growth factor production by ma caque granulosa cells from pre-and periovulatory follicles. J Clin Endocrinol Metab. 1997;82(7):2135-2142.
 
38. Demeestere I, Simon P, Emiliani S, et al.:Orthotopic and heterotopic ovarian tissue transplantation. Hum Reprod Update. 2009;15(6):649-665.
PubMed
39. Cuvillier O, Pirianov G, Kleuser B, et al.:Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996;381(6585):800-803.
PubMed
40. Soleimani R, Heytens E, Oktay K:Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants. PloS One. 2011;6(4):e19475.
PubMed
41. Zhang Y, Xia X, Yan J, et al.:Mesenchymal stem cell-derived angiogenin promotes primodial follicle survival and angiogenesis in transplanted human ovarian tissue. Reprod Biol Endocrinol. 2017;15(1):18.
 
42. Manavella DD, Cacciottola L, Desmet CM, et al.:Adipose tissue-derived stem cells in a fibrin implant enhance neovascularization in a peritoneal grafting site:a potential way to improve ovarian tissue transplantation. Hum Reprod. 2018;33(2):270-279.
 
43. Su J, Ding L, Cheng J, et al.:Transplantation of adipose-derived stem cells combined with collagen scaffolds restores ovarian function in a rat model of premature ovarian insufficiency. Hum Reprod. 2016;31(5):1075-1086.
 
44. Damous LL, Nakamuta JS, Saturi de Carvalho AE, et al.:Scaffold-based delivery of adipose tissue-derived stem cells in rat frozen-thawed ovarian autografts:preliminary studies in a rat model. J Assist Reprod Genet. 2015;32(8):1285-1294.
 
P.232 掲載の参考文献
1. Ben-Aharon I, Meizner I, Granot T, et al.:Chemotherapy-induced ovarian failure as a prototype for acute vascular toxicity. Oncologist. 2012;17(11):1386-1393.
PubMed
2. Meirow D, Dor J, Kaufman B, et al.:Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod. 2007;22(6):1626-1633.
PubMed
3. Lambertini M, Horicks F, Del Mastro L, et al.:Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients:From biological evidence to clinical application. Cancer Treat Rev. 2019;72:65-77.
PubMed
4. Poggio F, Lambertini M, Bighin C, et al.:Potential mechanisms of ovarian protection with gonadotropin-releasing hormone agonist in breast cancer patients:A Review. Clin Med Insights Reprod Health. 2019;13:1179558119864584.
PubMed
5. Blumenfeld Z:How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist. 2007;12(9):1044-1054.
PubMed
6. Hasky N, Uri-Belapolsky S, Goldberg K, et al.:Gonadotrophin-releasing hormone agonists for fertility preservation:unraveling the enigma? Hum Reprod. 2015;30(5):1089-1101.
PubMed
7. Kitajima Y, Endo T, Nagasawa K, et al.:Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology. 2006;147(2):694-699.
 
8. Moore HC, Unger JM, Phillips KA, et al.:Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923-932.
PubMed
9. Leonard RCF, Adamson DJA, Bertelli G, et al.:GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer:the Anglo Celtic Group OPTION trial. Ann Oncol. 2017;28(8):1811-1816.
PubMed
10. Demeestere I, Brice P, Peccatori FA, et al.:No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy:Final long-term report of a prospective randomized trial. J Clin Oncol. 2016;34(22):2568-2574.
 
11. Lambertini M, Boni L, Michelotti A, et al.:Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival:A randomized clinical trial. JAMA. 2015;314(24):2632-2640.
PubMed
12. Elgindy EA, El-Haieg DO, Khorshid OM, et al.:Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage:a randomized controlled trial. Obstet Gynecol. 2013;121(1):78-86.
 
13. Munster PN, Moore AP, Ismail-Khan R, et al.:Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during(neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30(5):533-538.
PubMed
14. Gerber B, von Minckwitz G, Stehle H, et al.:Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy:the GBG 37 ZORO study. J Clin Oncol. 2011;29(17):2334-2341.
PubMed
15. Oktay K, Harvey BE, Partridge AH, et al.:Fertility preservation in patients with cancer:ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994-2001.
 
16. Shandley LM, Spencer JB, Fothergill A, et al.:Impact of tamoxifen therapy on fertility in breast cancer survivors. Fertil Steril. 2017;107(1):243-252.
 
17. Yamazaki R, Inokuchi M, Ishikawa S, et al.:Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women. Springerplus. 2015;4:425.
PubMed
18. Lambertini M, Ceppi M, Poggio F, et al.:Ovarian suppression using luteinizing hormonereleasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients:a meta-analysis of randomized studies. Ann Oncol. 2015;26(12):2408-2419.
PubMed
19. Munhoz RR, Pereira AA, Sasse AD, et al.:Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for earlystage breast cancer:A systematic review and meta-analysis. JAMA Oncol. 2016;2(1):65-73.
PubMed
20. Turner NH, Partridge A, Sanna G, et al.:Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients:the benefit remains uncertain. Ann Oncol. 2013;24(9):2224-2235.
 
21. Elgindy E, Sibai H, Abdelghani A, et al.:Protecting ovaries during chemotherapy through gonad suppression:A systematic review and meta-analysis. Obstet Gynecol. 2015;126(1):187-195.
PubMed
22. Lambertini M, Cinquini M, Moschetti I, et al.:Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients:A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer. 2017;71:25-33
 
23. Paluch-Shimon S, Pagani O, Partridge AH, et al.:Second international consensus guidelines for breast cancer in young women(BCY2). Breast. 2016;26:87-99.
PubMed
24. Munoz M, Santaballa A, Segui MA, et al.:SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients(2016). Clin Transl Oncol. 2016;18(12):1229-1236.
PubMed
25. Coates AS, Winer EP, Goldhirsch A, et al.:Tailoring therapies-improving the management of early breast cancer:St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533-1546.
PubMed
26. Network NCC. 2017 National Comprehensive Cancer Network Guidelines-Breast Cancer (https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf)
 
27. Peccatori FA, Azim HA Jr, Orecchia R, et al.:Cancer, pregnancy and fertility:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi160-170.
 
28. Network NCC. 2017 National Comprehensive Cancer Network Guidelines Adolescent and Young Adult(AYA)Oncology (https://www.nccn.org/professionals/physician_gls/pdf/aya.pdf)
 
29. 日本乳癌学会(編):乳癌診療ガイドライン2018年版. 金原出版, 2018.
 
30. 日本癌治療学会(編):小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン2017年版. 金原出版, 2017.
 
P.239 掲載の参考文献
1. Socie G, Salooja N, Cohen A, et al.:Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003;101:3373-3385.
PubMed
2. Nakagawa K, Kanda Y, Yamashita H, et al.:Preservation of ovarian function by ovarian shielding when undergoing total body irradiation for hematopoietic stem cell transplantation:a report of two successful cases. Bone Marrow Transplant. 2006;37:583-587.
PubMed
3. Nakagawa K, Kanda Y, Yamashita H, et al.:Ovarian shielding allows ovarian recovery and normal birth in female hematopoietic SCT recipients undergoing TBI. Bone Marrow Transplant. 2008;42:697-699.
PubMed
4. Kanda Y, Wada H, Yamasaki R, et al.:Protection of ovarian function by two distinct methods of ovarian shielding for young female patients who receive total body irradiation. Ann Hematol. 2014;93(2):287-292.
PubMed
5. 永井良明, 堤箸真人, 松崎仁ほか:側臥位卵巣遮蔽による全身照射(TBI)の改良点:タングステンシートによる肺ブロック. 臨床放射線. 2012;57:1109-1105.
 
6. Ashizawa M, Akahoshi Y, Nakano H, et al.:Updated clinical outcomes of hematopoietic stem cell transplantation using myeloablative total body irradiation with ovarian shielding to preserve fertility. Biol Blood Marrow Transplant. 2019;25(12):2461-2467.
PubMed
7. Scott BL, Sandmaier BM, Storer B, et al.:Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia:a retrospective analysis. Leukemia. 2006;20:128-135.
 
8. Kanda Y, Sakamoto K, Ashizawa M, et al.:Risks and benefits of ovarian shielding in female patients undergoing TBI:a decision analysis. Bone Marrow Transplant. 2011;46:1145-1147.
PubMed
9. Ishibashi N, Soejima T, Kawaguchi H, et al.:National survey of myeloablative total body irradiation prior to hematopoietic stem cell transplantation in Japan:survey of the Japanese Radiation Oncology Study Group(JROSG). J Radiat Res. 2018;59:477-483.
 
P.248 掲載の参考文献
1. 日本癌治療学会(編):小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン2017年版. 金原出版, 2017.
 
2. 日本産科婦人科学会/日本病理学会(編):子宮頸癌取扱い規約第4版病理編. 金原出版, 2017.
 
3. Bhatla N, Aoki D, Sharma DN, et al.:Cancer of the cervix uteri. Int J Gynecol Obstet. 2018;143(Suppl. 2):22-36.
 
4. 日本婦人科腫瘍学会(編):子宮頸癌治療ガイドライン2017年版. 金原出版, 2017.
 
5. National Comprehensive Cancer Network:Cervical Cancer Guideline(Version 5. 2019)NCCN Clinical Practice Guidelines in Oncology (https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf)
 
6. Baalbergen A, Smedts F, Helmerhorst TJM:Conservative therapy in microinvasive adenocarcinoma of the uterine cervix is justified:an analysis of 59 cases and a review of the literature. Int J Gyneco1 Cancer. 2011;21:1640-1645.
 
7. Al-Kalbani M, McVeigh G, Nagar H, et a1:Do FIGO stage IA and small(</=2cm) IB1 cervical adenocarcinomas have a good prognosis and warrant less radical surgery? Int J Gyneco1 Cancer. 2012;22:291-295.
 
8. Marchiole P, Benchaib M, Buenerd A, et al.:Oncological safety of laparoscopic-assisted vaginal radical trachelectomy(LARVT or Dargent's operation):A comparative study with laparoscopic-assisted vaginal radical hysterectomy(LARVH). Gynecol Oncol. 2007;106:132-141.
PubMed
9. Smith JR, Boyle DC, Corless DJ, et al.:Abdominal radical trachelectomy:a new surgical technique for the conservative management of cervical carcinoma. Br J Obstet Gynecol. 1997;104:1196-1200.
 
10. 小林裕明:センチネルリンパ節:子宮頸がんに対する広汎子宮頸部摘出術とロボテックサージャリーにおけるセンチネルノード・ナビゲーションサージャリーの応用. 産婦人科の実際. 2014;63(8):1125-1134.
 
11. 小林裕明:当科における腹式子宮頸部摘出術の適格基準と疾病予後について. 日本婦人科腫瘍学会雑誌. 2011;29:668-674.
 
12. Okugawa K, Kobayashi H, Sonoda K, et al.:Oncologic and obstetric outcomes and complications during pregnancy after fertility sparing abdominal trachelectomy for cervical cancer:a retrospective review. Int J Clin Oncol. 2017;22:340-346.
PubMed
13. Sato S, Aoki D, Kobayashi H, et al.:Questionnaire survey of the current status of radical trachelectomy in Japan. Int J Clin Oncol. 2011;16(2):141-144.
PubMed
14. Nishio H, Fujii T, Kameyama K, et al.:Abdominal radical trachelectomy as a fertility-sparing procedure in women with early stage cervical cancer in a series of 61 women. Gynecol Oncol 115:51-55, 2009
 
15. Li J, Wu X, Li X, et al.:Abdominal radical trachelectomy:Is it safe for IB1 cervical cancer with tumors >/= 2cm? Gynecol Oncol. 2013;131:87-92.
 
16. Bentivegna E, Gouy S, Maulard A, et al.:Oncological outcomes after fertility-sparing surgery for cervical cancer:a systematic review. Lancet Oncol. 2016;17:e240-e253.
PubMed
17. Wethington SL, Sonoda Y, Park KJ, et al.:Expanding the indications for radical trachelectomy:a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters. Int J Gynecol Cancer. 2013;23:1092-1098.
PubMed
18. Kato T, Takashima A, Kasamatsu T, et al.;Gynecologic Oncology Study Group of the Japan Clinical Oncology Group.:Clinical tumor diameter and prognosis of patients with FIGO stage IBl cervical cancer(JCOG0806-A). Gynecol Oncol. 2015;137:34-39.
 
19. Togami S, Kamio M, Kobayashi H, et a.:Is it possible to perform less radical surgery for invasive uterine cervical cancer? Gynecol Obstet Invest. 2015;81(3):251-255.
 
20. Kunieda F, Kasamatsu T, Arimoto T, et al.:Non-randomized confirmatory trial of modified radical hysterectomy for patients with tumor diameter 2 cm or less FIGO Stage IB1 uterine cervical cancer:Japan Clinica1 0ncology Group Study(JCOG1101). Jpn J Clin Onco1. 2015;45:123-126.
PubMed
21. 小林裕明:あなたにもできる最先端の婦人科手術:広汎子宮頸部摘出術. 臨床婦人科産科. 2014;68(7):672-679.
 
22. 神尾真樹, 小林裕明:広汎子宮頸部摘出術の適応と限界. 産婦人科の実際. 2015;64(13):1997-2005.
 
23. Boss EA, van Golde RJ, Beerendonk CC, et al.:Pregnancy after radical trachelectomy:a real option? Gynecol Oncol. 2005;99(Suppl. 1):152-156.
 
24. Li J, Li Z, Wang H, et al.:Radical abdominal trachelectomy for cervical malignancies:surgical, oncological and fertility outcomes in 62 patients. Gynecol Oncol. 2011;121:565-570.
 
P.257 掲載の参考文献
1. 日本婦人科腫瘍学会:子宮頸癌治療ガイドライン2017年版:金原出版, 2011, pp. 104-106.
 
2. Kasamatsu T, Onda T, Sawada M, et al.:Radical hysterectomy for FIGO stage IIB cervical cancer:clinicopathological characteristics and prognostic evaluation. Gynecol Oncol. 2009;114(1):69-74.
PubMed
3. Shimada M, Kigawa J, Nishimura R, et al.:Ovarian metastasis in carcinoma of the uterine cervix. Gynecol Oncol. 2006;101(2):234-237.
PubMed
4. Nakanishi T, Ishikawa H, Suzuki Y, et al.:A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 2000;79(2):289-293.
 
5. Yamamoto R, Okamoto K, Yukiharu T, et al.:A study of risk factors for ovarian metastases in stage Ib-IIIb cervical carcinoma and analysis of ovarian function after a transposition. Gynecol Oncol. 2001;82(2):312-316.
PubMed
6. 澤田守男:子宮頚癌に対する卵巣温存の適応と限界. 日本産科婦人科学会雑誌. 2006;58:313-319.
 
7. 櫻木範明ほか:子宮頸癌の卵巣転移と広汎性子宮全摘術児の卵巣温存について. 産科と婦人科. 1996;9(55):1223-1228.
 
8. Chambers SK, Chambers JT, Kier R, et al:Sequelae of lateral ovarian transposition in irradiated cervical cancer patients. Int J Radiat Oncol Biol Phys. 1991;20(6):1305-1308.
PubMed
9. van Beurden M, Schuster-Uitterhoeve AL, Lammes FB:Feasibility of transposition of the ovaries in the surgical and radiotherapical treatment of cervical cancer. Eur J Surg Oncol. 1990;16(2):141-146.
 
10. Swift BE, Leung E, Vicus D, et al.:Laparoscopic ovarian transposition prior to pelvic radiation for gynecologic cancer. Gynecol Oncol Rep. 2018; 24:78-82.
PubMed
11. 柿木成子ほか:子宮頸癌治療のControversy卵巣温存はどこまで可能か? 産科と婦人科. 2003;70(5):574-578.
 
12. Hwang JH, Yoo HJ, Park SH, et al:Association between the location of transposed ovary and ovarian function in patients with uterine cervical cancer treated with(postoperative or primary)pelvic radiotherapy. Fertil Steril. 2012;97(6):1387-1393.
PubMed
13. Anderson B, LaPolla J, Turner D, et al:Ovarian transposition in cervical cancer. Gynecol Oncol. 1993;49(2):206-214.
PubMed
14. 大野勉ほか:当科におけるResidual Ovary Syndromeの臨床的検討. 日本産科婦人科学会雑誌. 1994;46(4):353-356.
 
15. 田中真由美ほか:子宮頸癌の広汎子宮全摘術おける卵巣移動術についての検討. 日本産科婦人科学会雑誌. 1999;51(7):447-452.
 
16. Nguyen L, Brewer CA, DiSaia PJ:Ovarian metastasis of stage IB1 squamous cell cancer of the cervix after radical parametrectomy and oophoropexy. Gynecol Oncol. 1998;68(2):198-200.
PubMed
17. Shigematsu T, Ohishi Y, Fujita T, et al:Metastatic carcinoma in a transposed ovary after radical hysterectomy for a stage 1B cervical adenosquamous cell carcinoma. Case report. Eur J Gynaecol Oncol. 2000;21(4):383-386.
 
18. Morice P, Haie-Meder C, Pautier P, et al:Ovarian metastasis on transposed ovary in patients treated for squamous cell carcinoma of the uterine cervix:report of two cases and surgical implications. Gynecol Oncol. 2001;83(3):605-607.
PubMed
19. Delotte J, Ferron G, Kuei TL, et al:Laparoscopic management of an isolated ovarian metastasis on a transposed ovary in a patient treated for stage IB1 adenocarcinoma of the cervix. J Minim Invasive Gynecol. 2009;16(1):106-108.
 
20. Janse JA, Sie-Go DM, Schreuder HW:Ovarian metastasis in a transposed ovary 10 years after primary cervical cancer:the importance of histologic examination and review of literature. BMJ Case Rep. 2011 Jun 17;2011 doi:10.1136/bcr.04.2011.4155.
 
21. Hoekman EJ, Broeders EABJ, Louwe LA, et al.:Ovarian function after ovarian transposition and additional pelvic radiotherapy:A systematic review. Eur J Surg Oncol. 2019;45(8):1328-1340.
PubMed
P.267 掲載の参考文献
1. Yamagami W, Nagase S, Takahashi F, et al.:Clinical statistics of gynecologic cancers in Japan. J Gynecol Oncol. 2017;28:e32.
PubMed
2. 榎本隆之:婦人科腫瘍委員会報告. 2017年患者年報. 日本産婦人科学会雑誌. 2019;71:669-724.
 
3. Ushijima K, Yahata H, Yoshikawa H, et al.:Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007;25:2798-2803.
PubMed
4. Park JY, Kim DY, Kim JH, et al.:Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer(KGOG 2002). Eur J Cancer. 2013;49:868-874.
PubMed
5. Yamagami W, Susumu N, Makabe T, et al.:Is repeated high-dose medroxyprogesterone acetate(MPA)therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? J Gynecol Oncol. 2018;29:e21.
PubMed
6. Takeshima N, Hirai Y, Yano K, et al.:Ovarian metastasis in endometrial carcinoma. Gynecol Oncol. 1998;70:183-187.
PubMed
7. 笹川基, 田村希, 塚田清二ほか:子宮体癌における重複癌. 日本産婦人科学会雑誌. 2000;52:756-760.
 
8. Kamikatahira S, Jobo T, Kuramoto H:Endometrial carcinoma with synchronous ovarian malignancy differentiation between independent and metastatic carcinoma. Int J Clin Oncol 1996;1:100-108.
 
9. Nishimura N, Hachisuga T, Yokoyama M, et al.:Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary. J Obstet Gynaecol Res. 2005;31:120-126.
PubMed
10. 平野卓朗, 山上亘, 真壁健ほか:子宮体癌の術前子宮鏡検査と腹腔細胞診. 日本臨床細胞学会雑誌. 2019;58:196-201.
Medical*Online
11. 日本婦人科腫瘍学会(編):子宮体がん治療ガイドライン2018年版. 金原出版, 2018.
 
12. Inoue O, Hamatani T, Susumu N, et al.:Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia. Reprod Biol Endocrinol. 2016;14:2.
PubMed
P.278 掲載の参考文献
1. 国立がん研究センターがん対策情報センター:地域がん登録全国推計値 (https://ganjoho.jp/reg_stat/statistics/dl/index.html#incidence4pref)
 
2. 日本婦人科腫瘍学会(編):卵巣がん治療ガイドライン2015年版. 金原出版, 2015.
 
3. 日本産科婦人科学会婦人科腫瘍委員会:婦人科腫瘍委員会報告2017年度患者年報. 日本産婦人科学会雑誌. 2019;71:669-806.
 
4. NCCN Ovarian cancer including fallopiantube cancer and primary peritoneal cancer, version3. 2019-Nov. 26, 2019 (https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf)
 
5. Colombo N, Sessa C, du Bois A, et al.:ESMO-ESGO consensus conference recommendations on ovarian cancer:pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;00:1-34.
 
6. Bentivega E, Gouy S, Maulard A, et al.:Fertility-sparing surgery in epithelial ovarian cancer:a systematic review of oncological issues. Ann oncol. 2016;27:1994-2004.
 
7. Kajiyama H, Shibata K, Mizuno M, et al.:Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. Br J Cancer. 2011;105:288-1294.
 
8. Fruscio R, Ceppi L, Corso S, et al.:Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer. Br J Cancer. 2016;115:641-648.
PubMed
9. Melamed A, Rizzo AE, Notecki R, et al.:All-cause mortality after fertility-sparing surgery for stageI epithelial ovarian cancer. Obstet Gynecol. 2017;130:71-79.
 
10. Satoh T, Hatae M, Watanabe Y, et al.:Outcomes of fertility-sparing surgery for stageI epithelial ovarian cancer:A proposal for patient selection. J Clin Oncol. 2010;28:1727-1732.
 
11. Bentivega E, Fruscio R, Roussin S, et al.:Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer:review of the results of an international multicenter study comprising 545 patients. Fertil Steril. 2015;104:1319-1324.
 
12. Garcia-Soto AE, Boren T, Wingo SN, et al.:Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? Am J Obstet Gynecol. 2012;242:e1-e5.
 
13. Soper JT, Johnson P, Johnson V, et al.:Comprehensive restating laparotomy in women with apparent early ovarian carcinoma. Obstet Gynecol. 1992;80:949-953.
 
14. Buchsbaum HJ, Brady MF, Delgado G, et al.:Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet. 1989;169:226-232.
PubMed
15. Helewa ME, Krepart GV, Potpcki R:Staging laparotomy in early epithelial ovarian carcinoma. Am J Obstet Gynecol. 1986;154:282-286.
 
16. Young RC, Decker DG, Wharton JT, et al.:Staging laparotomy in early ovarian cancer. JAMA. 1983;250:3072-3076.
PubMed
17. Ayhan A, Gultekin M, Celik NY, et al.:Occult metastasis in early ovarian cancers:risk factors and associated prognosis. Am J Obstet Gynecol. 2007;81:e1-e6.
 
18. Benjamin I, Morgan MA, Rubin SC:Occult bilateral involvement in stageI epithelial ovarian cancer. Gynecol Oncol. 1999;72:288-291.
 
19. Meza-Perez S, Randall TD:Immunological functions of the omentum. Trends Immunol. 2017;38:526-536.
PubMed
20. Arie AB, McNally L, Kapp DS, et al.:The omentum and omentectomy in epithelial ovarian cancer:a reappraisal:partII-The role of omentectomy in the staging and treatment of apparent early stage epithelial ovarian cancer. Gynecol Oncol. 2013;131:784-790.
 
21. McNally L, Teng NN, Kapp DS, et al.:Does omentectomy in epithelial ovarian cancer affect survival? An analysis of the Surveillance, Epidemiology, and End Results database. Int J Gynecol Cancer. 2015;25:607-615.
PubMed
22. Ovarian cancer surgical procedure. GOG Surgical Manual. 2010, pp. 16-17.
 
23. Lee JY, Kim HS, Chung HH, et al.:The role of omentectomy and random peritoneal biopsies as part of comprehensive surgical staging in apparent early-stage epithelial ovarian cancer. Ann Surg Oncol. 2014;21:2762-2766.
PubMed
24. Kleppe M, Wang T, Van Gorp T, et al.:Lymph node metastasis in stagesI and II ovarian cancer:a review. Gynecol Oncol. 2011;123:610-614.
 
25. Rouzier R, Bergzoll C, Brun JL, et al.:The role of lymph node resection in ovarian cancer:analysis of the Surveillance, Epidemiology, and End Results(SEER)database. BJOG. 2010;117:1451-1458.
PubMed
26. Chan J, Munro E, Cheung M, et al.:Association of lymphadenectomy and survival in stageI ovarian cancer patients. Obstet Gynecol. 2007;109:12-19.
 
27. 日本癌治療学会(編):小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン2017年版. 金原出版, 2017.
 
28. AlHilli MM, Dowdy SC, Weaver AL, et al.:Incidence and factors associated with synchronous ovarian and endometrial cancer:a population-based case-control study. Gynecol Oncol. 2012;125:109-1013.
PubMed
29. Zaino R, Whitney C, Brady MF, et al.:Simultaneously detected endometrial and ovarian carcinomas-a prospective clinicopathologic study of 74 cases:a gynecologic oncology group study. Gynecol Oncol. 2001;83:355-362.
 
30. Eifel P, Hendrickson M, Ross J, et al.:Simultaneous presentation of carcinoma involving the ovary and the uterine corpus. Cancer. 1982;50:163-170.
PubMed
31. Vergote I, Brabanter J, Fyles A, et al.:Prognostic importance of degree of differentiation and cyst rupture in stageI invasive epithelial ovarian carcinoma. Lancet. 2001;357:176-182.
 
32. 町田弘子, 松尾高司, 三上幹夫:I期卵巣癌に対し術中破綻が与える生存予後への影響:JSGO-JSOG joint study. 第61回日本婦人科腫瘍学会学術講演会抄録. 日本婦人科腫瘍学会雑誌. 2019;37:390-391.
 
33. Ceppi L, Galli F, Lamanna M, et al.:Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms. Gynecol Oncol. 2019;152:346-352.
PubMed
P.286 掲載の参考文献
1. Di Santo M, Tarozzi N, Nadalini M, et al.:Human sperm cryopreservation:Update on techniques, effect on DNA Integrity, and Implications for ART. Adv Urol. 2012;2012:854837.
PubMed
2. Hezavehei M, Sharafi M, Kouchesfahani HM, et al.:Sperm cryopreservation:A review on current molecular cryobiology and advanced approaches. Reprod Biomed Online. 2018;37:327-339.
PubMed
3. Lansac J, Royere D:Follow-up studies of children born after frozen sperm donation. Hum Reprod Update. 2001;7:33-37.
PubMed
4. Aizpurua J, Medrano L, Enciso M, et al.:New permeable cryoprotectant-free vitrification method for native human sperm. Hum Reprod. 2017;32:2007-2015.
PubMed
5. Le MT, Nguyen TTT, Nguyen TT, et al.:Cryopreservation of human spermatozoa by vitrification versus conventional rapid freezing:Effects on motility, viability, morphology and cellular defects. Eur J Obstet Gynecol Reprod Biol. 2019;234:14-20.
PubMed
6. Polge C:Fertilizing capacity of bull spermatozoa after freezing at 79 degrees C. Nature. 1952;169:626-627.
PubMed
7. Bunge RG, Sherman JK:Fertilizing capacity of frozen human spermatozoa. Nature. 1953;172:767-768.
PubMed
8. Iizuka R, Sawada Y:Successful artificial insemination with frozen-pooled human semen. Jpn J Fertil Steril. 1958;3:241-246.
 
9. Rives N, Perdrix A, Hennebicq S, et al.:The semen quality of 1158 men with testicular cancer at the time of cryopreservation:results of the French National CECOS Network. J Androl. 2012;33:1394-1401.
PubMed
10. Janczewski Z, Bablok L:Semen characteristics in pubertal boys. I. Semen quality after first ejaculation. Arch Androl. 1985;15:199-205.
 
11. Stensheim H, Klungsoyr K, Skjaerven R, et al.:Birth outcomes among offspring of adult cancer survivors:a population-based study. Int J Cancer. 2013;133:2696-2705.
PubMed
12. Al-Jebari Y, Glimelius I, Berglund Nord C, et al.:Cancer therapy and risk of congenital malformations in children fathered by men treated for testicular germ-cell cancer:A nationwide register study. PLoS Med. 2019;16:e1002816.
 
13. Eiser C, Arden-Close E, Morris K, et al.:The legacy of sperm banking:how fertility monitoring and disposal of sperm are linked with views of cancer treatment. Hum Reprod. 2011;26:2791-2798.
PubMed
14. Negoro H, Matsui Y, Nakayama T, et al.:Sperm cryopreservation:Clinical and fertility outcomes in male oncological patients with germ cell tumors or hematological disorders. Reprod Med Biol. 2018;17:500-503.
PubMed
15. Shin T, Kobayashi T, Shimomura Y, et al.:Microdissection testicular sperm extraction in Japanese patients with persistent azoospermia after chemotherapy. Asian J Androl. 2014;16:107-111.
 
16. Yumura Y, Tsujimura A, Okada H, et al.:Current status of sperm banking for young cancer patients in Japanese nationwide survey. Asian J Androl. 2018;20:336-341.
PubMed
17. Yumura Y, Tsujimura A, Okada H, et al.:Recognition and attitudes of Japanese hematologists on sperm banking before chemotherapy:present status from nationwide questionnaire survey. Int J Clin Oncol. 2019;24:94-102.
PubMed
P.289 掲載の参考文献
1. Ginsberg JP:Educational paper:theeffect of cancer on fertility, the assessment of fertility and fertility preservation for pediatric patients. Eur J Pediatr. 2011;6:703-708.
 
2. Donnez J, Dolmans MM, Demylle D, et al.:Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405-1410.
PubMed
3. Pont J, Albrecht W:Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril. 1997;68:1-5.
PubMed
4. Rendtorff R, Hohmann C, Reinmuth S, et al.:Hormone and sperm analyses after chemoand radiotuerpy in childhood and adolescence. Klin Padiatr. 2010;222:145-149.
 
5. Avarbock MR, Brinster CJ, Brinster RL:Reconstitution of spermatogenesis from frozen spermatogonial stem cells. Nat Med. 1996;2:693-696.
PubMed
6. Shinohara T, Inoue K, Ogonuki N, et al.:Birth of offspring following transplantation of cryopreserved immature testicular pieces and in-vitro microinsemination. Hum Reprod. 2002;17:3039-3045.
PubMed
7. Wu X, Goodyear SM, Abramowitz LK, et al.:Fertile offspring derived from mouse spermatogonial stem cells cryopreserved for more than 14 years. Hum Reprod. 2012;27:1249-1259.
PubMed
8. Wyns C, Van Langendonckt A, Wese FX, et al.:Long-term spermatogonial survival in cryopreserved and xenografted immature human testicular tissue. Hum Reprod. 2008;23:2402-2414.
PubMed
9. Amorim CA, Curaba M, Van Langendonckt A, et al.:Vitrification as an alternative means of cryopreserving ovarian tissue. Reprod Biomed Online. 2011;23:160-186.
PubMed
10. Poels J, Van Langendonckt A, Many MC, et al.:Vitrification preserves proliferation capacity in human spermatogonia. Hum Reprod. 2013;28:578-589.
PubMed
11. Sato T, Katagiri K, Gohbara A, et al.:In vitro production of functional sperm in cultured neonatal mouse testes. Nature. 2011;471:504-507.
PubMed
12. Yokonishi T, Sato T, Komeya M, et al.:Offspring production with sperm grown in vitro from cryopreserved testis tissues. 2014;Nat Commum:5:4320.
 
13. 山中弘行, 湯村寧, 小川毅彦:精巣組織の凍結. 2016;Pharma Medica:34:31-34.
Medical*Online
14. Fayomi AP, Peters K, Sukhwani M, et al.:Autologous grafting of cryopreserved prepubertal rhesus testis produces sperm and offspring. Science. 2019;363:1314-1319.
PubMed
P.294 掲載の参考文献
1. 日本生殖医療学会(編):生殖医療の必修知識2017年版. 杏林舍, 2017, pp. 232-234.
 
2. Jarow JP, Espeland MA, Lipshultz LI:Evaluation of the azoospermic patient. J Urol. 1989;142:62-65.
 
3. Flannigan R, Bach PV, Schlegel PN:Microdissection testicular sperm extraction. Transl Androl Urol. 2017;6:745-752.
PubMed
4. Kanto S, Yamasaki K, Iwamoto T:Progressing management of non-obstructive azoospermia in the era of microdissection testicular sperm extraction. Reprod Med Biol. 2014;13:119-125.
PubMed
5. Dabaja AA, Schlegel PN:Microdissection testicular sperm extraction:An update. Asian J Androl. 2013;15:35-39.
PubMed
6. Silber SJ, Nagy ZP, Liu J, et al.:Conventional in vitro fertilization versus intracytoplasmic sperm injection for patients requiring microsurgical sperm aspiration. Human Reprod. 1994;9:1705-1709.
PubMed
7. Silber SJ, Steirteghem AC, Van Liu J, et al.:High fertilization and pregnancy rate after intracytoplasmic sperm injection with spermatozoa obtained from testicle biopsy. Human Reprod. 1995;10:148-152.
 
8. Devroey P, Liu J, Nagy Z, et al.:Pregnancies after testicular sperm extraction and intracytoplasmic sperm injection in non-obstructive azoospermia. Hum Reprod. 1995;10:1457-1460.
PubMed
9. Schlegel PN:Testicular sperm extraction:Microdissection improves sperm yield with minimal tissue excision. Hum Reprod. 1999;14:131-135.
PubMed
10. 湯村寧, 岩本晃明, 辻村晃ほか:厚生労働省子ども・子育て支援推進調査研究事業 我が国における男性不妊に対する検査・治療に関する調査研究. 平成27年度総括・分担研究報告書. 2016, pp. 29-62.
 
11. Jungwirth A, Diemer T, Dohle GR, et al.:EAU Guidelines on male infertility. Europian Associcatio of Urlogy, 2012.
 
12. 日本癌治療学会(編):小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン2017年版. 金原出版, 2017.
 
13. Shin T, Kobayashi T, Shimomura Y, et al.:Microdissection testicular sperm extraction in Japanese patients with persistent azoospermia after chemotherapy. Int J Clin Oncol. 2016;21:1167-1171.
PubMed
14. Kawai K, Nishiyama H:Preservation of fertility of adult male cancer patients treated with chemotherapy. Int J Clin Oncol. 2019;24:34-40.
PubMed
15. Hsiao W, Stahl PJ, Osterberg EC, et al.:Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction:The Weill Cornell experience. J Clin Oncol. 2011;29:1607-1611.
PubMed
16. Shiraishi K, Matsuyama H:Microdissection testicular sperm extraction and salvage hormonal treatment in patients with postchemotherapy azoospermia. Urology. 2014;83:100-106.
PubMed
17. Jacobsen FM, Fode M, Sonksen J, et al.:Successful extraction of sperm cells after autologous bone marrow transplant:a case report. Scand J Urol. 2019;53:174-175.
PubMed
18. Kanto S, Hasegawa K, Ishizawa K, et al.
 
19. Gurkan H, Kucukdurmaz F, Akman T, et al.:Screening for Y chromosome microdeletion in a nonobstructive azoospermic male patient with allogeneic bone marrow transplantation from his sister. Case Rep Med. 2010;2010:4.
 
20. Dar S, Orvieto R, Levron J, et al.:IVF outcome in azoospermic cancer survivors. Eur J Obstet Gynecol Reprod Biol. 2018;220:84-87.
PubMed
21. Gauthier-Fisher A, Kauffman A, Librach CL:Potential use of stem cells for fertility preservation. Andrology. 2019 Sep. 27
 
22. Fayomi AP, Peters K, Sukhwani M, et al.:Autologous grafting of cryopreserved prepubertal rhesus testis produces sperm and offspring. Science. 2019;363:1314-1319.
PubMed
23. Sato T, Katagiri K, Gohbara A, et al.:In vitro production of functional sperm in cultured neonatal mouse testes. Nature. 2011;471:504-508.
PubMed

第4章 がん・生殖医療を支える医療

P.306 掲載の参考文献
1. Lee YY, Roberts CL, Dobbins T, et al.:Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008:a population-based linkage study. BJOG. 2012;119(13):1572-1582.
PubMed
2. Smith LH, Danielsen B, Allen ME, et al.:Cancer associated with obstetric delivery:results of linkage with the California cancer registry. Am J Obstet Gynecol. 2003;189:1128-1135.
 
3. Pavlidis NA:Coexistence of pregnancy and malignancy. Oncologist. 2002;7:279-287.
PubMed
4. Pentheroudakis G, Pavlidis N:Cancer and pregnancy:poena magna, not anymore. Eur J Cancer. 2006;42:126-140.
 
5. Hoellen F, Reibke R, Hornemann K, et al.:Cancer in pregnancy. Part I:basic diagnostic and therapeutic principles and treatment of gynecological malignancies. Arch Gynecol Obstet. 2011;285(1):195-205.
PubMed
6. Van Calsteren K, Heyns L, De Smet F, et al.:Cancer during pregnancy:an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010;28:683-689.
PubMed
7. Lee YY, Roberts CL, Young J, et al.:Using hospital discharge data to identify incident pregnancy-associated cancers:a validation study. BMC Pregnancy Childbirth. 2013;13:37.
PubMed
8. Smith LH, Danielsen B, Allen ME, et al.:Cancer associated with obstetric delivery:results of linkage with the California cancer registry. Am J Obstet Gynecol. 2003;189(4):1128-1135.
 
9. Murgia F, Marinaccio M, Cormio G, et al.:Pregnancy related cancer in Apulia. A population based linkage study. Eur J Obstet Gynecol Reprod Biol X. 2019;3:100025.
PubMed
10. Kobayashi Y, Tabata T, Ikeda T, et al.:A Japanese survey of malignant disease in pregnancy. Int J Clin Oncol. 2019;24(3):328-333.
 
11. Pavlidis NA:Coexistence of pregnancy and malignancy. Oncologist. 2002;7:279-287.
PubMed
12. Insinga RP, Glass AG, Rush BB:Diagnoses and outcomes in cervical cancer screening:a population-based study. Am J Obstet Gynecol. 2004;191:105-113.
PubMed
13. Demeter A, Sziller I, Csapo Z, et al.:Outcome of pregnancies after cold-knife conization of the uterine cervix during pregnancy. Eur J Gynaecol Oncol. 2002;23:207-210.
PubMed
14. Yang KY:Abnormal pap smear and cervical cancer in pregnancy. Clin Obstet Gynecol. 2012;55(3):838-848.
PubMed
15. Economos K, Veridiano NP, Delke I, et al.:Abnormal cervical cytology in pregnancy:A 17-year experience. Obstet Gynecol. 1993;81(6):915-918.
 
16. Selleret L, Mathevet P:Precancerous cervical lesions during pregnancy:diagnostic and treatment. J Gynecol Obstet Biol Reprod(Paris). 2008;37(Suppl. 1):S131-138.
 
17. Frederic A, Sileny NH, Mina MG, et al.:Management of cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2015;29(5):741-753.
 
18. Sood AK, Sorosky JI, Krogman S, et al.:Surgical management of cervical cancer compli cating pregnancy:a case-control study. Gynecol Oncol. 1996;63(3):294-298.
 
19. Takushi M, Moromizato H, Sakumoto K, et al.:Management of invasive carcinoma of the uterine cervix associated with pregnancy:outcome of intentional delay in treatment. Gynecol Oncol. 2002;87(2):185-189.
PubMed
20. Germann N, Haie-Meder C, Morice P, et al.:Management and clinical outcomes of pregnant patients with invasive cervical cancer. Ann Oncol. 2005;16(3):397-402.
PubMed
21. Alouini S, Rida K, Mathevet P:Cervical cancer complicating pregnancy:implications of laparoscopic lymphadenectomy. Gynecol Oncol. 2008;108(3):472-477.
PubMed
22. Nisker JA, Shubat M, Stage IB:Cervical carcinoma and pregnancy:report of 49 cases. Am J Obstet Gynecol. 1983;145(2):203-206.
PubMed
23. Greer BE, Easterling TR, McLennan DA, et al.:Fetal and maternal considerations in the management of stage I-B cervical cancer during pregnancy. Gynecol Oncol. 1989;34(1):61-65.
 
24. Morice P, Uzan C, Gouy S, et al.:Gynaecological cancers in pregnancy. Lancet. 2012;379(9815):558-569.
PubMed
25. 村田雄二:改訂3版合併症妊娠. メディカ出版, 2011.
 
26. Kuczkowski KM:The safety of anaesthetics in pregnant women. Expert Opin Drug Saf. 2006;5(2):251-264
 
27. Cardonick E, Iacobucci A:Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5(5):283-291.
PubMed
28. Loibl S, Han SN, von Minckwitz G, et al.:Treatment of breast cancer during pregnancy:an observational study. Lancet Oncol. 2012;13:887-896.
PubMed
29. Morice P, Uzan C, Gouy S, et al.:Gynaecological cancers in pregnancy. Lancet. 2012;379:558-569.
PubMed
30. Cibula D, Potter R, Planchamp F, et al.:The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. Int J Gynecol Cancer. 2018;28(4):641-655.
PubMed
31. Ngu SF, Ngan HY:Chemotherapy in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;33:86-101.
PubMed
32. Durodola JI:Administration of cyclophosphamide during late pregnancy and early lactation:a case report. J Natl Med Assoc. 1979;71(2):165-166.
PubMed
33. Aviles A, Neri N:Hematological malignancies and pregnancy:a final report of children who received chemotherapy in utero. Clin Lymphoma. 2001;2(3):173-177.
PubMed
34. Nulman I, Laslo D, Fried S, et al.:Neurodevelopment of children exposed in utero to treatment of maternal malignancy. Br J Cancer. 2001;85(11):1611-1618
 
P.311 掲載の参考文献
1. Hudson MM, Armenian SH, Armstrong GT, et al.:Optimization of health and extension of lifespan through childhood cancer survivorship research. J Clin Oncol. 2018;36:2133-2134.
 
2. 国立がん研究センターがん情報サービス:小児・AYA 集計報告書. がん診療連携拠点病院等院内がん登録全国集計 (https://ganjoho.jp/reg_stat/statistics/brochure/hosp_c_registry.html)
 
3. Brignardello E, Felicetti F, Castiglione A, et al.:Endocrine health conditions in adult survivors of childhood cancer:the need for specialized adult-focused follow-up clinics. Eur J Endocrinol. 2013;168:465-472.
PubMed
4. Bhakta N, Liu Q, Ness KK, et al.:The cumulative burden of surviving childhood cancer:an initial report from the St Jude Lifetime Cohort Study(SJLIFE). Lancet. 2017;390:2569-2582.
PubMed
5. Flerlage JE, Metzger ML, Bhakta N, et al.:The management of Hodgkin lymphoma in adolescents and young adults:burden of disease or burden of choice? Blood. 2018;132:376-384.
PubMed
6. Ness KK, Kirkland JL, Gramatges MM, et al.:Premature physiologic aging as a paradigm for understanding increased risk of adverse health across the lifespan of survivors of childhood cancer. J Clin Oncol. 2018;36:2206-2215.
PubMed
7. Children's Oncology Group:Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, Version 5. 0. (http://www.survivorshipguidelines.org)
 
8. van Dorp W, Mulder RL, Kremer LC, et al.:Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer:A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. J Clin Oncol. 2016;34:3440-3450.
 
9. Skinner R, Mulder RL, Kremer LC, et al.:Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors:a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Lancet Oncol. 2017;18:e75-e90.
 
10. 横谷進, 落合亮太, 小林信秋ほか;日本小児科学会移行期の患者に関するワーキンググループ:小児期発症疾患を有する患者の移行期医療に関する提言. 日本小児科学会雑誌. 2014;118:98-106.
 
11. Miyoshi Y, Yorifuji T, Shimizu C, et al.:A nationwide questionnaire survey targeting Japanese pediatric endocrinologists regarding transitional care in childhood, adolescent, and young adult cancer survivors. Clin Pediatr Endocrinol. 2020;29(2):55-62.
 
12. Coccia PF, Pappo AS, Beaupin L, et al.:Adolescent and young adult oncology, Version 2. 2018, NCCN Clinical practice guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:66-97.
 
13. 日本小児内分泌学会CCS委員会:小児がん経験者(CCS)のための医師向けフォローアップガイド(ver1. 2). 日本小児科学会雑誌. 2012;116:1976-1977(2016年7月1日改訂).
 
14. van Dorp W, Haupt R, Anderson RA, et al.:Reproductive function and outcomes in female survivors of childhood, adolescent, and young adult cancer:a review. J Clin Oncol. 2018;36:2169-2180.
 
15. Kenney LB, Antal Z, Ginsberg JP, et al.:Improving male reproductive health after childhood, adolescent, and young adult cancer:Progress and future directions for survivorship research. J Clin Oncol. 2018;36(21):2160-2168.
 
16. 関口将軌, 三善陽子, 左合治彦:小児がん既往妊娠. 周産期医学. 2016;46(10):1263-1266.
Medical*Online
17. 安岡稔晃, 杉山隆:がんサバイバーと周産期リスク. 日本がん・生殖医療学会誌. 2020;3(1):9-13.
 
18. 日本癌治療学会(編):小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン2017年版. 金原出版, 2017, pp. 110-112.
 
19. Miyoshi Y, Yorifuji T, Horikawa R, et al.:Gonadal function, fertility, and reproductive medicine in childhood and adolescent cancer patients:a national survey of Japanese pediatric endocrinologists. Clin Pediatr Endocrinol. 2016;25:45-57.
PubMed
20. Miyoshi Y, Yorifuji T, Horikawa R, et al.:Childbirth and fertility preservation in childhood and adolescent cancer patients:a second national survey of Japanese pediatric endocrinologists. Clin Pediatr Endocrinol. 2017;26(2):81-88.
PubMed
P.316 掲載の参考文献
1. Gupta AA, Edelstein K, Albert-Green A, et al.:Assessing information and service needs of young adults with cancer at a single institution:the importance of information on cancer diagnosis, fertility preservation, diet, and exercise. Support Care Cancer. 2013;21(9):2477-2484.
 
2. Nakayama K, Liu P, Detry M, et al.:Receiving information on fertility-and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation:changes in perceived importance over time. Biol Blood Marrow Transplant. 2009;15(11):1465-1474.
PubMed
3. Thewes B, Meiser B, Taylor A, et al.:Fertility-and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol. 2005;23(22):5155-5165.
PubMed
4. Wright CI, Coad J, Morgan S, et al.:The fertility information needs of teenagers and young adults with cancer. Eur J Cancer Care(Engl). 2014;23(2):189-198.
 
5. Miyashita M, Ohno S, Kataoka A, et al.:Unmet information needs and quality of life in young breast cancer survivors in Japan. Cancer Nurs. 2015;38(6):E1-E11.
PubMed
6. Cohen L, Hamer J, Helwig C, et al.:Formal evaluation of PYNK:Breast Cancer Program for Young Women-the patient perspective. Current Oncol. 2016;23(2):E10-E108.
 
7. Niemasik EE, Letourneau J, Dohan D, et al.:Patient perceptions of reproductive health counseling at the time of cancer diagnosis:a qualitative study of female California cancer survivors. J Cancer Surviv. 2012;6(3):324-332.
PubMed
8. Baysal O, Bastings L, Beerendonk CCM, et al.:Decision-making in female fertility preservation is balancing the expected burden of fertility preservation treatment and the wish to conceive. Hum Reprod. 2015;30(7):1625-1634.
PubMed
9. Razzano A, Revelli A, Delle Piane L, et al.:Fertility preservation program before ovarotoxic oncostatic treatments:role of the psychological support in managing emotional aspects. Gynecol Endocrinol. 2014;30(11):822-824.
PubMed
10. Lee RJ, Wakefield A, Foy S, et al.:Facilitating reproductive choices:the impact of health services on the experiences of young women with breast cancer. Psychooncology. 2011;20(10):1044-1052.
PubMed
11. Miedema B, Easley J, Robinson LM:Do current cancer follow-up care practices meet the needs of young adult cancer survivors in Canada? A qualitative inquiry. Curr Oncol. 2013;20(1):14-22.
 
12. 総合的な思春期・若年成人(AYA)世代のがん対策のあり方に関する研究. 厚生労働科学研究成果(文献番号20167024A)(https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=20167024A)
 
13. 国立がん研究センターがん情報サービスがん登録・統計:小児・AYA 世代のがんの罹患率 (https://ganjoho.jp/reg_stat/statistics/stat/child_aya.html)
 
P.323 掲載の参考文献
1. Loren AW, Mangu PB, Beck LN, et al.:American Society of Clinical Oncology. Fertility preservation for patients with cancer:American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500-2510.
 
2. Jones G, Hughes J, Mahmoodi N, et al.:What factors hinder the decision-making process for women with cancer and contemplating fertility preservation treatment? Hum Reprod Update. 2017;23:433-457.
PubMed
3. 鈴木直, 高井泰, 野澤美江子ほか(編):ヘルスケアプロバイダーのためのがん・生殖医療. メディカ出版, 2019.
 
4. 日本癌治療学会(編):小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン2017年版. 金原出版, 2017.
 
5. 日本がん・生殖医療学会(編):乳がん患者の妊娠出産と生殖医療に関する診療の手引き2017年版. 金原出版, 2017.
 
6. Schover LR, Rhodes MM, Baum G, et al.:Sisters peer counseling in reproductive issues after treatment(SPIRIT):a peer counseling program to improve reproductive health among African American breast cancer survivors. Cancer. 2011;117(21):4983-4992.
PubMed
P.329 掲載の参考文献
1. 意思決定の支援ツール (https://www.clg.niigata-u.ac.jp/~arimori/kaken/?page_id=99)
 
2. 日本がん・生殖医療学会. 一般・患者のみなさま (http://j-sfp.org/public_patient/index.html)
 
3. 鈴木直, 高井泰, 野澤美江子ほか(編) :ヘルスケアプロバイダーのためのがん・生殖医療. メディカ出版, 2019, pp. 178-179.
 
4. 日本がん・生殖医療学会. 地域医療連携の紹介(Oncofertility Consortium Japan:各地域ネットワーク活動状況)(http://www.j-sfp.org/cooperation/index.html)
 
5. 生殖機能温存がん治療法の革新的発展に向けた総合的プラットフォームの形成研究班(代表:大須賀穣)(編):がん患者の妊孕性温存のための診療マニアル. 金原出版, 2019, pp. 81-83.
 
6. 森明子:生殖看護の立場から. 日本生殖看護学会誌. 2012;9(1):67-70.
Medical*Online
7. 日本産科婦人科学会. 医学的適応による未授精卵子, 胚(受精卵)および卵巣組織凍結・保存に関する見解 (http://www.jsog.or.jp/modules/statement/index.php?content_id=23)
 
P.337 掲載の参考文献
1. The Oncofertility! Psycho-Education And Couple Enrichment(O! PEACE)therapy:An intervention study protocol for a randomized controlled trial in Japan. International Federation of Fertility Societies 2015 International Meeting;2015 26 Apr, Yokohama, JAPAN.
 
2. Deshpande NA, Braun IM, Meyer FL:Impact of fertility preservation counseling and treatment on psychological outcomes among women with cancer:A systematic review. Cancer. 2015;121(22):3938-3947.
 
3. Lawson AK, Klock SC, Pavone ME, et al.:Psychological counseling of female fertility preservation patients. J Psychosoc Oncol. 2015;33(4):333-353.
PubMed
4. Logan S, Perz J, Ussher J, et al.:Clinician provision of oncofertility support in cancer patients of a reproductive age:A systematic review. Psychooncology. 2018;27(3):748-756.
PubMed
5. Anazodo A, Laws P, Logan S, et al.:How can we improve oncofertility care for patients? A systematic scoping review of current international practice and models of care. Human reproduction update. 2019;25(2):159-179.
PubMed
6. Logan S, Anazodo A:The psychological importance of fertility preservation counseling and support for cancer patients. Acta Obstet Gynecol Scand. 2019;98(5):583-597.
PubMed
7. Goncalves V, Quinn GP:Review of fertility preservation issues for young women with breast cancer. Hum Fertil(Camb). 2016;19(3):152-165.
 
8. Benedict C, Thom B, Kelvin JF:Fertility preservation and cancer:challenges for adolescent and young adult patients. Curr Opin Support Palliat Care. 2016;10(1):87-94.
 
9. Daly C, Micic S, Facey M, et al.:A review of factors affecting patient fertility preservation discussions & decision-Making from the perspectives of patients and providers. Eur J Cancer Care(Engl). 2019;28(1):e12945.
PubMed
10. Jones G, Hughes J, Mahmoodi N, et al.:What factors hinder the decision-making process for women with cancer and contemplating fertility preservation treatment? Hum Re prod Update. 2017;23(4):433-457.
 
11. Wang Y, Anazodo A, Logan S:Systematic review of fertility preservation patient decision aids for cancer patients. Psychooncology. 2019;28(3):459-467.
PubMed
12. Logan S, Perz J, Ussher JM, et al.:A systematic review of patient oncofertility support needs in reproductive cancer patients aged 14 to 45 years of age. Psychooncology. 2018;27(2):401-409.
PubMed
13. Logan S, Perz J, Ussher JM, et al.:Systematic review of fertility-related psychological distress in cancer patients:Informing on an improved model of care. Psychooncology. 2019;28(1):22-30.
 
14. Akizuki N, Yamawaki S, Akechi T, et al.:Development of an impact thermometer for use in combination with the distress thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients. J Pain Symptom Manage. 2005;29(1):91-99.
PubMed
15. 小泉智恵:乳がん女性とその夫を対象とした妊孕性温存の心理教育プログラムO!PEACE:成果を活かすためには. 日本がん・生殖医療学会誌. 2020;3:84.
 
16. The Practice Committee of the American Society for Reproductive Medicine:Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy:a committee opinion. Fertil Steril. 2013;100(5):1214-1223.
 
P.346 掲載の参考文献
1. Loren AW, Mangu Pb, Beck LN, et al.:Fertility preservation for patients with cancer:American Society of Clinical Onchology Clinical Practice Guideline Update. J Clin Onchol. 2013;31(19):2500-2510.
 
2. 奈良和子:がん・生殖医療の心理支援-妊孕性温存の医学的適応と社会的適応. 子育て支援と心理臨床. 2019;18:52-57.
 
3. Ishikawa H, Yamazaki Y:How applicable is western models of patient-physician relationship in Asia? Changing patient-physician relationship in contemporary Japan. IJJS. 2005;14:84-93.
 
4. fujimori M, Uchitomi Y:Preferences of cancer patients regarding communication of bad news:a systematic literature review. Jpn J Clin Oncol. 2009;9(4):3201-3216.
 
5. Gorman JR, Su HI, Roberts SC, et al.:Experiencing reproductive concerns as a female cancer survivor is associated with depression. Cancer. 2015;121(6):935-942.
PubMed
6. Letourneau JM:Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710-1717.
PubMed
7. 平山貴敏, 清水研:精神腫瘍を含むAYA世代のがん患者に対する心理社会的問題と支援. 泌尿器外科. 2018;31(12):1625-1629.
 
8. van den Berg MH, Overbeek A, Lambalk CB, et al.:Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve. Hum Reprod. 2018 Jul 6. doi:10.1093/humrep/dey229.
 
9. Piaget J:The theory of stages in cognitive development. In:Measurement and Piaget(Green DR, Ford MP, Flamer GB, eds). McGraw-Hill, 1971.
 
10. Bibace R, Walsh ME:Development of children's concepts of illness. Pediatrics. 1980;66(6):912-917.
 
11. 奈良和子, 小泉智恵ほか:妊孕性温存における心理支援と心理職の役割. 日本がん・生殖医療学会誌. 2018;1(1):57-60.
 
12. 厚生労働省科学研究費補助金がん対策推進総合研究事業「総合的な思春期・若年成人(AYA)世代のがん対策のあり方に関する研究」班:AYA世代のがん対策に関する政策提言資料5. 2015.
 
13. ジャネット・ジャフェ(小倉智子訳):子守歌が歌いたくて-不妊を理解して対処するために. バベルプレス, 2007.
 
14. Lawson AK, Klock SC, Pvone ME, et al.:Psychological counseling of female fertility preservation patients. J Psychosoc Oncol. 2015;33(4):333-353.
 
15. 菅沼慎一郎, 浦野由平:諦める事に対する認知の発達的特徴と自己肯定感および人生満足度との関連. 臨床心理学 95. 2016;16(5):600-605.
 
16. Colleoni M, Mandala M, Peruzzotti G, et al.:Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet, 2000;356(9238):1326-1327.
PubMed
17. Banerjee R, Tsiapali E:Occurrence and recall rates of fertility discussions with young breast cancer patients. Supportive care in cancer. Support Care Cancer. 2016;24(1):163-171.
PubMed
18. Hagedoorn M, Kuijer RG, BUunk BP, et al.:Marital satisfaction in patients with cancer:Does support from intimate partners benefit those who need it the most? Health Psychol. 2000;19(3):274-282.
 
19. 小泉智恵, 大須賀穣, 鈴木直:44. 短期間のうちに多くの意思決定を迫られる患者にどう関わる?臨床心理士の立場から. がん生殖医療ハンドブック妊孕性・生殖機能温存診療の実践ガイド. メディカ出版, 2017, p. 300.
 
20. ポーリン・ボス(南山浩二訳):「さよなら」のない別れ別れのない「さよなら」:曖昧な喪失. 学文社, 2005, p. 347.
 
21. Doka KJ:Disenfranchised Grief:Recognizing Hidden Sorrow. Lexington Books, 1989, p. 347.
 
P.350 掲載の参考文献
1. Boyajian RN, Grose A, Grenon N, et al.:Desired elements and timing of cancer survivorship care:one approach may not fit all. J Oncol Pract 2014;10(5):293-298.
PubMed
2. Pasternak B, Svanstrom H, Hviid A:Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med. 2013;368(9):814-823.
PubMed
P.357 掲載の参考文献
1. Gardino SL, Jeruss JS, Woodruff TK:Using decision trees to enhance interdisciplinary team work:the case of oncofertility. J Assist Reprod Genet. 2010;27(5):227-231.
PubMed
2. Ito Y, Shiraishi E, Sugimoto K, et al.:The utility of decision trees in oncofertility care in Japan. J Adolesc Young Adult Oncol. 2017;6:186-189.
PubMed
3. Sanada Y, Harada M, Osuga Y et al.:A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients. J Obstet Gynaecol Res. 2019;45:2021-2028.
PubMed
4. 菊田昇:この赤ちゃんにもしあわせを. 菊田医師赤ちゃんあっせん事件の記録. 人間と歴史社, 1978.
 
5. Florence赤ちゃん縁組. 養子縁組対談(1):ある医師の"違法行為"から始まった! (https://engumi.florence.or.jp/news/2017/03/1155)
 
6. 日本財団ハッピーゆりかごプロジェクト:養子縁組をした762人の親子のこえ. 2019. (https://happy-yurikago.net/wpcore/wp-content/uploads/data/190402.pdf)
 
7. NHK厚生文化事業団:新しい絆の作り方 特別養子縁組・里親入門. (https://www.npwo.or.jp/video/13172)
 
8. 吉田奈穂子:子どものいない夫婦のための養子縁組ガイド 制度の仕組みから真実告知まで. 明石書店, 2016.
 
9. 吉田奈穂子:子どものいない夫婦のための里親ガイド 家庭を必要とする子どもの親になる. 明石書店, 2015.
 
10. 後藤絵里:産まなくても, 育てられます. 講談社, 2016.
 
11. 日本財団ハッピーゆりかごプロジェクトとは～子どもたちにあたたかい家庭を～. (https://happy-yurikago.net/about/)
 
12. 厚生労働省:特別養子縁組制度について (https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000169158.html)
 
13. Gardino SL, Russel AE, Woodruff TK:Adoption After Cancer:Adoption Agency Attitudes and Perspectives on the Potential to Parent Post-Cancer. Oncofertility Ethical, Legal, Social, and Medical Perspectives. Springer, 2010.
 
14. the Oncofertility Consortium:CANCER FRIENDLY ADOPTION AGENCIES (http://oncofertility.northwestern.edu/files/documents/cancer-friendly-adoption-agencies)
 
15. Shiraishi E, Sugimoto K, Suzuki N, et al.:Study of the awareness of adoption as a family-building option among oncofertility stakeholders in Japan. J Glob Oncol. 2018;4:1-7.
 
16. 厚生労働省:特別養子縁組制度について 5. 養子縁組あっせん事業者一覧(令和元年10月1日現在)(https://www.mhlw.go.jp/content/11900000/000560466.pdf)
 
17. Sugimoto K, Anami R, Suzuki N, et al.:A study of the criteria for young cancer survivors to become foster or adoptive parents in Japan. 日本生殖心理学会誌, 2018;4:12-19.
 
18. 杉本公平:市民公開講座『「がんサバイバーと里親・特別養子縁組」家族を作るもう一つの選択肢』を開催して-アンケート結果報告と今後の展望の考察. 日本がん・生殖医療学会誌. 2019;2:22-26.
 
P.367 掲載の参考文献
1. Desandes E, Clavel J, Berger C, et al.:Cancer incidence among children in France, 1990-1999. Pediatr Blood Cancer 2004;43(7):749-757.
PubMed
2. Recklitis C, O'Leary T, Diller L:Utility of routine psychological screening in the childhood cancer survivor clinic. Clin Oncol. 2003;21(5):787-792.
PubMed
3. Rauck AM, Green DM, Yasui Y, et al.:Marriage in the survivors of childhood cancer:a preliminary description from the Childhood Cancer Survivor Study. Med Pediatr Oncol. 1999;33(1):60-63.
PubMed
4. Stuber ML, Meeske KA, Krull KR, et al.:Prevalence and predictors of posttraumatic stress disorder in adult survivors of childhood cancer. Pediatrics. 2010;125(5):e1124-e1134.
PubMed
5. Zebrack BJ, Mills J, Weitzman TS:Health and supportive care needs of young adult cancer patients and survivors. J Cancer Surviv. 2007;1(2):137-145.
PubMed
6. Zeltzer LK, Lu Q, Leisenring W, et al.:Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors:a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2008;17(2):435-446.
PubMed
7. Warner EL, Nam GE, Zhang Y, et al.:Health behaviors, quality of life, and psychosocial health among survivors of adolescent and young adult cancers. J Cancer Surviv. 2016;10(2):280-290.
 
8. Geenen MM, Cardous-Ubbink MC, Kremer LC, et al.:Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007;297(24):2705-2715.
PubMed
9. Bhakta N, Liu Q, Ness KK, et al.:The cumulative burden of surviving childhood cancer:an initial report from the St Jude Lifetime Cohort Study(SJLIFE). Lancet. 2017;390(10112):2569-2582.
PubMed
10. Hudson MM, Ness KK, Gurney JG, et al.:Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309(22):2371-2381.
PubMed
11. Gibson TM, Mostoufi-Moab S, Stratton KL, et al.:Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99:a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2018;19(12):1590-1601.
 
12. Armstrong GT, Liu Q, Yasui Y, et al.:Late mortality among 5-year survivors of childhood cancer:a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2328-2338.
PubMed
13. Reulen RC, Winter DL, Frobisher C, et al.:Long-term cause-specific mortality among survivors of childhood cancer. JAMA. 2010;304(2):172-179.
PubMed
14. Miyoshi Y, Ohta H, Hashii Y, et al.:Endocrinological analysis of 122 Japanese childhood cancer survivors in a single hospital. Endocr J. 2008;55(6):1055-1063.
 
15. Mostoufi-Moab S, Seidel K, Leisenring WM, et al.:Endocrine abnormalities in aging survivors of childhood cancer:A report from the Childhood Cancer Survivor Study. J Clin Oncol. 2016;34(27):3240-3247.
PubMed
16. Patterson BC, Wasilewski-Masker K, Ryerson AB, et al.:Endocrine health problems detected in 519 patients evaluated in a pediatric cancer survivor program. J Clin Endocrinol Metab. 2012;97(3):810-818.
 
17. Brignardello E, Felicetti F, Castiglione A, et al.:Endocrine health conditions in adult survivors of childhood cancer:the need for specialized adult-focused follow-up clinics. Eur J Endocrinol. 2013;168(3):465-472.
PubMed
18. Hayek S, Gibson TM, Leisenring WM, et al.:Prevalence and predictors of frailty in childhood cancer survivors and siblings:A report from the Childhood Cancer Survivor Study. J Clin Oncol. 2020;38(3):232-247.
PubMed
19. Mulrooney DA, Yeazel MW, Kawashima T, et al.:Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer:retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.
 
20. Nottage KA, Ness KK, Li C, et al.:Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia-From the St. Jude Lifetime Cohort. Br J Haematol. 2014;165(3):364-374.
PubMed
21. Meacham LR, Sklar CA, Li S, et al.:Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy:a report for the Childhood Cancer Survivor Study. Arch Intern Med. 2009;169(15):1381-1388.
PubMed
22. Sklar CA, Mertens AC, Mitby P, et al.:Premature menopause in survivors of childhood cancer:a report from the childhood cancer survivor study. J Natl Cancer Inst. 2006;98(13):890-896.
PubMed
23. Chemaitilly W, Mertens AC, Mitby P, et al.:Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006;91(5):1723-1728.
PubMed
24. Neglia JP, Friedman DL, Yasui Y, et al.:Second malignant neoplasms in five-year survivors of childhood cancer:childhood cancer survivor study. J Natl Cancer Inst. 2001;93(8):618-629.
PubMed
25. Armenian SH, Robison LL:Childhood cancer survivorship:an update on evolving paradigms for understanding pathogenesis and screening for therapy-related late effects. Curr Opin Pediatr. 2013;25(1):16-22.
PubMed
26. Jenkinson HC, Hawkins MM, Stiller CA, et al.:Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain. Br J Cancer. 2004;91(11):1905-1910.
PubMed
27. Olsen JH, Garwicz S, Hertz H, et al.:Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries. BMJ. 1993;307(6911):1030-1036.
 
28. Moskowitz CS, Chou JF, Wolden SL, et al.:Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32(21):2217-2223.
 
29. Tonorezos ES, Henderson TO:Clinical guidelines for the care of childhood cancer survivors. Children(Basel). 2014;1(2):227-240. (http://www.survivorshipguidelines.org/)
 
P.374 掲載の参考文献
1. United Nations Population Fund:Report of the international conference on population and development(ICPD). 1994 Sep. 5-13, Cairo, Egypt. United Nations, New York, 1994.
 
2. 兵藤智佳:人口政策におけるReproductive Rights概念について. 国際協力研究. 2002;18:8-16.
 
3. リード・ボーランド(著), 房野桂(訳):性と生殖に関する権利. 明石書店, 1997, pp. 1-200.
 
4. "Gender and reproductive rights". WHO. int. Archived from the original on 2009-07-26. Retrieved 2010-08-29.
 
5. 日本がん・生殖医療学会(編):乳がん患者の妊娠・出産と生殖医療に関する診療の手引き2017年版. 金原出版, 2017, pp. 12-19.
 
6. 日本癌治療学会(編):小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン2017年版. 金原出版, 2017, pp. 22-24.
 
7. Ethics Committee of the American Society for Reproductive Medicine. Electronic address:ASRM@asrm. org1;Ethics Committee of the American Society for Reproductive Medicine. Posthumous retrieval and use of gametes or embryos:an Ethics Committee opinion. Fertil Steril. 2018;110:45-49.
PubMed
8. Nakhuda GS:Posthumous assisted reproduction. Semin Reprod Med. 2010;28:329-35.
PubMed
9. 伊佐智子:凍結保存精子を用いた死後生殖の法的及び倫理的検討. 生命倫理. 2006;16:154-160.
 
10. 認知請求事件 松山地裁 平成15年11月12日判決. 判例時報. Vol. 1840, p. 85.
 
11. 認知請求控訴事件 高松高裁 平成16年7月16日判決. 判例時報. Vol. 1868, p. 69.
 
12. 認知請求事件 最高裁第二小法廷 平成18年9月4日. 裁判所判例Watch (https://kanz.jp/hanrei/detail/33488/)
 
13. McCandless J, Sheldon S:The human fertilisation and embryology act(2008) and the tenacity of the sexual family form. Modern Law Review. 2010;73:175-207. (https://doi.org/10.1111/j.1468-2230.2010.00790.x)
 
14. 日本受精着床学会倫理委員会報告. 凍結精子を用いた死後生殖についての見解(11月1日) (http://www.jsfi.jp/about/pdf/ethics20041101_01.pdf)
 
15. 日本産科婦人科学会:精子の凍結保存に関する見解 (http://www.jsog.or.jp/modules/statement/index.php?content_id=26)
 
16. 日本産科婦人科学会:ヒト胚および卵子の凍結保存と移植に関する見解(2014年6月改定版)(http://www.jsog.or.jp/modules/statement/index.php?content_id=22)
 
P.379 掲載の参考文献
1. 日本癌治療学会(編):小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン2017年版. 金原出版, 2017.
 
2. 厚生労働省:がん対策推進基本計画. 2018 (https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000196975.pdf)
 
3. Furui T, Takenaka M, Makino H, et al.:An evaluation of the Gifu Model in a trial for a new regional oncofertility network in Japan, focusing on its necessity and effects. Reprod Med Biol. 2015;15(2):107-113.
 
4. Ataman LM, Rodrigues JK, Marinho RM, et al.:Creating a global community of practice for oncofertility. J Global Oncol. 2015;published online ahead:1-14.
 
5. 岐阜県がん患者支援情報提供サイト. 岐阜県がん・生殖医療ネットワーク (https://hosp.gifu-u.ac.jp/center/gan/img/seisyokuiryo.pdf)
 
6. 岐阜県がん患者支援情報提供サイト. 将来の出産に備えて (http://gifugan.net/syussan/)
 
7. 岐阜大学医学部附属病院がんセンター. がん・生殖医療外来:がん治療と妊娠について (https://hosp.gifu-u.ac.jp/center/gan/reproduction/gan-seisyoku.html)
 
8. 滋賀がん・生殖医療ネットワーク. 滋賀がん・生殖医療ネットワークのご利用方法 (http://www.sumsog.jp/of-net-shiga/how-to)
 
9. 滋賀がん・生殖医療ネットワーク. OF-Net Shiga登録施設一覧表 (http://www.sumsog.jp/files/shisetsu-20150701.pdf)
 
10. 埼玉県がん・生殖医療ネットワーク(SORNET). がん患者さん・免疫疾患患者さんなどに対する妊孕性温存外来のお知らせ (http://og-smc.com/fp/)
 
11. 三重がん・生殖医療ネットワーク. ご相談・受診方法 (http://www.medic.mie-u.ac.jp/oncofertility/contact.html)
 
12. 日本がん・生殖医療学会(JSFP). Oncofertility Consortium Japan:各地域ネットワークの活動状況 (http://www.j-sfp.org/cooperation/index.html)
 
13. 古井辰郎:がん患者の妊孕性温存のための診療マニュアル(大須賀穣編). 金原出版, 2019, pp. 92-93.
 
14. 古井辰郎:がん・生殖医療に関する情報提供体制の現状と課題. 第57回日本癌治療学会学術集会. ワークショップ8 AYA世代がんの諸問題とその対応. 2019年10月25日, 福岡市.
 
15. 日本生殖心理学会. がん・生殖医療専門心理士養成講座開講のご案内 (https://www.jsrp.org/course/cancer_repro_course.html)
 
16. 日本生殖心理学会. 日本生殖心理学会認定 がん・生殖医療専門心理士名簿 (https://www.jsrp.org/course/cancer_repro_list.html)
 
P.387 掲載の参考文献
1. von Wolff M, Montag M, Dittrich R, et al.:Fertility preservation in women-a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network Ferti-PROTEKT. Arch Gynecol Obstet. 2011;284:427-435.
 
2. Germeyer A:Registerdaten 2015 Fertiprotekt. 2016 (https://static1.squarespace.com/static/560a328fe4b0e8c4f373857e/t/57206c853c44d81ea19e790b/1461742728020/registerdaten_fertiprotekt_2015.pdf)
 
3. von Wolff M, Capp E, Jauckus J, et al.:Timing of ovarian stimulation in patients prior to gonadotoxic therapy:an analysis of 684 stimulations. Eur J Obstet Gynecol Reprod Biol. 2016;199:146-149.
PubMed
4. Van der Ven H, Liebenthron J, Beckmann M, et al.:Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network:tissue activity, pregnancy and delivery rates. Hum Reprod. 2016;31:2031-2041.
 
5. 高井泰:ドイツ・スイスおよびオーストラリアにおける若年がん患者に対するがん・生殖医療の実際-わが国として学ぶべきものは? 日本がん・生殖医療学会誌, 2018;1:40-44.
 
6. Anazodo AC, Gerstl B, Stern CJ, et al.:Utilizing the experience of consumers in consultation to develop the Australasian Oncofertility Consortium Charter. J Adolesc Young Adult Oncol. 2016;5:232-239.
 
7. Anazodo AC, Stern CJ, McLachlan RI, et al.:A study protocol for the Australasian Oncofertility Registry:Monitoring referral patterns and the uptake, quality, and complications of fertility preservation strategies in Australia and New Zealand. J Adolesc Young Adult Oncol. 2016;5:215-225.
PubMed
8. Oncofertility Consortium (https://oncofertility.northwestern.edu)
 
9. Moravek MB, Confino R, Smith KN, et al.:Long-term outcomes in cancer patients who did or did not pursue fertility preservation. Fertil Steril. 2018;109:349-355.
PubMed
10. Rashedi AS, de Roo SF, Ataman LM, et al.:Survey of fertility preservation options available to patients with cancer around the globe. J Glob Oncol. 2018;4:1-16.
 
11. Inhorn MC, Birenbaum-Carmeli D, Westphal LM, et al.:Medical egg freezing:the importance of a patient-centered approach to fertility preservation. J Assist Reprod Genet. 2018;35:49-59.
PubMed
12. Kyono K, Hashimoto T, Toya M, et al.:A transportation network for human ovarian tissue is indispensable to success for fertility preservation. J Assist Reprod Genet. 2017;34:1469-1474.
 
13. The ESHRE Working Group on Oocyte Cryopreservation in Europe, Shenfield F, de Mouzon J, Scaravelli G, et al.:Oocyte and ovarian tissue cryopreservation in European countries:statutory background, practice, storage and use. Hum Reprod Open. 2017;2017(1):hox003.
 
14. Gellert SE, Pors SE, Kristensen SG, et al.:Transplantation of frozen-thawed ovarian tissue:an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Reprod Genet. 2018;35:561-570.
PubMed
15. Practice Committee of the American Society for Reproductive Medicine:Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy:a committee opinion. Fertil Steril. 2019;112:1022-1033.
 
16. 平成27-29年度厚生労働科学研究がん対策推進総合研究事業「総合的な思春期・若年成人(AYA)世代のがん対策のあり方に関する研究」斑:地域医療連携について. 2018 (http://www.j-sfp.org/aya/tiikirenkei/tiikirenkei.html)
 
17. 御舩美絵, 北野敦子:がん治療後に子どもを持つ可能性を残す-思春期・若年成人がん患者に対するがん生殖医療に要する時間および経済的負担に関する実態調査. 平成28年度がんサバイバーシップ研究助成金研究報告書. 2017 (https://www.fpcr.or.jp/pdf/p11/H28mihune.pdf)
 
18. 鈴木直(研究代表者):若年がん患者に対するがん・生殖医療(妊孕性温存治療)の有効性に関する調査研究. 厚生労働省子ども・子育て支援推進調査研究事業平成28年度総括・分担研究報告書. 2017 (http://www.marianna-u.ac.jp/file/houjin/news/h28kosodatekekka.pdf)
 
19. Yumura Y, Tsujimura A, Okada H, et al.:Current status of sperm banking for young cancer patients in Japanese nationwide survey. Asian J Androl. 2018;20:336-341.
PubMed
20. Sanada Y, Harada M, Kunitomi C, et al.:A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients. J Obstet Gynaecol Res. 2019;45:2021-2028.
PubMed

第5章 妊孕性温存療法の試み - ガイドラインなど

P.392 掲載の参考文献
1. 日本癌治療学会(編):小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン2017年版. 金原出版. 2017.
 
2. 太田邦明, 高橋俊文, 水沼英樹:卵巣組織凍結・移植の現状と未来. 日本がん生殖医療学会誌. 2018;1:23-26.
 
3. 高井泰:ドイツ・スイス及びオーストラリアにおける若年がん患者に対するがん. 生殖医療の実際-我が国として学ぶべきものは? 日本がん・生殖医療学会誌. 2018;1:40-44.
 
4. 杉本公平:市民公開講座「「がんサバイバーと里親・特別養子縁組」家族を作るもう一つの選択肢」を開催して～アンケート結果報告と今後の展望の考察～. 日本がん・生殖医療学会誌. 2019;2:22-26.
 
P.395 掲載の参考文献
1. 国際妊孕性温存学会(ISFP)ホームページ:(http://www.isfp-fertility.org)
 
2. 日本癌治療学会(編):小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン2017年版. 金原出版, 2017.
 
3. Masciangelo R, Bosisio C, Donnez J, et al.:Safety of ovarian tissue transplantation in patients with borderline ovarian tumors. Hum Re prod. 2018;33:212-219.
 
4. Stern CJ, Gook D, Hale LG, et al.:Delivery of twins following heterotopic grafting of frozen-thawed ovarian tissue. Hum Reprod. 2014;29:1828.
PubMed
5. Dittrich R, Hackl J, Lotz L, et al. :Pregnancies and live births after 20 transplantations of cryopreserved ovarian tissue in a single center. Fertil Steril. 2015;103:462-468.
 
6. Kristensen SG, Giorgione V, Humaidan P, et al.:Fertility preservation and refreezing of transplanted ovarian tissue-a potential new way of managing patients with low risk of malignant cell recurrence. Fertil Steril. 2017;107:1206-1213.
 
7. Cobo A, Garcia-Velasco JA, Coello A, et al.:Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105:755-764.
PubMed
8. Visser JA, Durlinger AL, Peters IJ, et al.:Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Mullerian hormone null mice. Endocrinology. 2007;148:2301-2308.
PubMed
9. Liu J, Van der Elst J, Van den Broecke R, et al.:Early massive follicle loss and apoptosis in heterotopically grafted newborn mouse ovaries. Hum Reprod. 2002;17:605-611.
PubMed
10. Ayuandari S, Winkler-Crepaz K, Paulitsch M, et al.:Follicular growth after xenotransplantation of cryopreserved/thawed human ovarian tissue in SCID mice:dynamic and molecular aspects. J Assist Reprod Genet 2016;33:1585-1593.
PubMed
11. Gavish Z, Spector I, Peer G, et al.:Follicle activation is a significant and immediate cause of follicle loss after ovarian tissue transplantation. J Assist Reprod Genet. 2018;35:61-69.
PubMed
12. Detti L, Fletcher NM, Saed GM, et al.:Xenotransplantation of pre-pubertal ovarian cortex and prevention of follicle depletion with anti-Mullerian hormone (AMH). J Assist Reprod Genet. 2018;35:1831-1841.
PubMed
P.400 掲載の参考文献
1. Oncofertility Consortium web サイト:(http://oncofertility.northwestern.edu/)
 
2. Rashedi AS, de Roo SF, Ataman LM, et al.:Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe. J Glob Oncol. 2018;4:1-16.
 
3. Anazodo A, Laws P, Logan S, et al.:How can we improve oncofertility care for patients? A systematic scoping review of current international practice and models of care. Hum Reprod Update. 2019;25(2):159-179.
PubMed
4. Anazodo A, Laws P, Logan S, et al.:The Development of an International Oncofertility Competency Framework:A Model to Increase Oncofertility Implementation. Oncologist. 2019;24(12):e1450-e1459.
 
5. Moravek MB, Appiah LA, Gomez-Lobo V, et al.:It takes a village:characteristics of and barriers to pediatric fertility preservation programs within the pediatric initiative network(PIN) of the oncofertility consortium. Fertil Steril. 2017;108(3):e85-e86.
 
6. Moravek MB, Appiah LC, Anazodo A, et al.:Development of a Pediatric Fertility Preservation Program:A Report From the Pediatric Initiative Network of the Oncofertility Consortium. J Adolesc Health. 2019;64(5):563-573.
 
7. Donnez J, Dolmans MM:Fertility Preservation in Women. N Engl J Med. 2017;377(17):1657-1665.
PubMed
8. Xiao S, Zhang J, Romero MM, et al.:In vitro follicle growth supports human oocyte meiotic maturation. Sci Rep. 2015;5:17323.
 
9. Laronda MM, Rutz AL, Xiao S, et al.:A bioprosthetic ovary created using 3D printed microporous scaffolds restores ovarian function in sterilized mice. Nat Commun. 2017;8:15261.
 
P.404 掲載の参考文献
1. von Wolff M, Andersen CY, Woodruff TK, et al.:FeriPROTEKT, Oncofertility Consosium and the Danish Fertility-Preservation networks -What Can We Learn from their experiences? Clin Med Insights Reprod Health. 2019;13:1-17.
 
2. The FertiPROTEKT Resister (https://fertiprotekt.com/fertiprotekt-the-register)
 
3. Liebenthron J, Montag M, Reinsberg J, et al.:Overnight ovarian tissue transportation for centralized cryobanking:a feasible option. RBMO. 2019;38:740-749.
 
4. 高井泰:ドイツ・スイスおよびオーストラリアにおける若年がん患者に対するがん・生殖医療の実際-わが国として学ぶべきものは? 日本がん・生殖医療学会誌. 2018;1(1):40-44.
 
5. von Wolff M, Montag M, Dittrich R, et al.:Fertility preservation in women-a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumors by the fertility preservation network FertiPROTEKT. Arch Gynecol Obste. 2011;284:427-435.
 
6. Schuring AN, Fehm T, Behringer K, et al.:Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I:indications for fertility preservation. Arch Gynecol Obste. 2018;297:241-255.
 
7. von Wolff M, Germeyer A, Liebenthron J, et al.:Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part II:fertility preservation techniques. Arch Gynecol Obste. 2018;297:257-267.
 
P.407 掲載の参考文献
1. Lee SJ, Schover LR, Partridge AH, et al.:American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. Journal of clinical oncology:official journal of the American Society of Clinical Oncology. 2006;24(18):2917-2931.
 
2. Loren AW, Mangu PB, Beck LN, et al.:Fertility preservation for patients with cancer:American Society of Clinical Oncology clinical practice guideline update. Journal of clinical oncology:official journal of the American Society of Clinical Oncology. 2013;31(19):2500-2510.
 
3. Oktay K, Harvey BE, Partridge AH, et al.:Fertility Preservation in Patients With Cancer:ASCO Clinical Practice Guideline Update. Journal of clinical oncology:official journal of the American Society of Clinical Oncology. 2018;36(19):1994-2001.
 

書評

最近チェックした商品履歴

Loading...